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General introduction and outline of thesis
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Fanconi anemia
Fanconi anemia (FA) is a autosomal recessive and X-linked inherited syndrome,
named after the Swiss pediatrician Guido Fanconi. In 1927, Fanconi reported the
first cases of the disease and he described three brothers who had a peculiar
combination of progressive aplastic anemia with several developmental anomalies
[1]. After then, many other cases of this disease have been studied and the
syndrome is currently characterized by progressive pancytopenia, congenital
anomalies such as abnormal thumbs and radii, cancer predisposition
(predominantly acute myeloid leukemia and squamous cell carcinoma), growth
retardation and hyperpigmentation of the skin [2–4]. Especially due to the life-
threatening bone marrow failure with a mean onset of about 8 years of age and the
elevated risk for developing acute myeloid leukemia (AML), life expectancy of FA
patients is reduced to an average of 25 years. The syndrome is very rare with a birth
prevalence of only 5-25 cases per million newborns.
Diagnosis, cellular phenotype and differential diagnosis
Fanconi anemia patients show a considerable phenotypic variability. Some patients
are not severely affected with mild anemia, no congenital anomalies and may have
a life expectancy of up to 50 years, whereas others have severe congenital
abnormalities and die from anemia or AML in the first decade of life. Even affected
siblings or monozygotic twins may show heterogeneous congenital anomalies.
Therefore, the clinical presentation may not be used for a reliable diagnosis and to
discriminate FA from clinically overlapping syndromes such as VATER/VACTERL
association [5], thrombocytopenia-absent radii (TAR) syndrome [6, 7] and Diamond-
Blackfan anemia [8, 9]. At the cellular level, however, FA patients show a more
uniform phenotype. FA patient-derived cells show spontaneous chromosome
instability and in addition are hypersensitive to the chromosome-breaking and
antiproliferative effects of DNA cross-linking agents such as mitomycin C (MMC) and
diepoxybutane (DEB) [2, 10]. This hypersensitivity to MMC or DEB is used to
diagnose FA and to discriminate the disease from the three clinically overlapping
conditions that are not hypersensitive to MMC or DEB.
     Although the MMC/DEB test has been proven to be a reliable tool for the
diagnosis of FA, patients with other syndromes may score positive to this test as
well. Nijmegen breakage syndrome (NBS) is a chromosomal instability syndrome
characterized by immune deficiency, microcephaly and hypersensitivity to ionizing
radiation. Since it has been reported that NBS can clinically mimic FA [11], mutation
screening in the gene that is responsible for Nijmegen breakage syndrome, NBS1, or
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a Western blot analysis of the NBS1 protein may be required to distinguish FA from
NBS.
Complementation groups and genetic heterogeneity
With the availability of the MMC test to discriminate FA cells from wild type cells, it
became possible to study potential locus heterogeneity of Fanconi anemia. The
principle of genetic heterogeneity lies in the fact that some gene products do not
perform a certain function ‘on their own’ but require the help of additional gene
products. These gene products then cooperate in a ‘biochemical pathway’. The
absence of one of the components – no matter which component – then
completely disrupts that pathway.
     When cells from different FA complementation groups are fused, this is expected
to result in a full restoration of the biochemical pathway. Although both cells miss a
critical component, that component is different for each cell. Fused together, a
complete set of functional genes is then present reestablishing the biochemical
pathway; the hybrid cells become resistant to MMC, similar as wild type cells.
However, when cells of identical complementation groups are fused, the pathway is
not restored and the cells remain hypersensitive to MMC.
     Extensive cell fusion studies have revealed that at least 11 complementation
groups are present: FA-A, B, C, D1, D2, E, F, G, I, J, and L [12–15]. This indicates that
Fanconi anemia is genetically a highly heterogeneous disorder and suggesting that
at least 11 gene products may be involved in the FA biochemical pathway.
However, as illustrated by the Ataxia telangiectasia (AT) disorder the rule ‘one
complementation group, one gene’ does not always apply. In AT patient-derived
cells evidence for 4 different complementation groups was found [16, 17], but
mutations in a single gene, ATM, were found in all complementation groups
suggesting that intragenic complementation must have contributed to this
phenomenon.
Cloning of FA genes
In 1992, a technique was developed to clone cDNAs for Fanconi anemia by the use
of functional complementation [18]. Similar to the assay used in complementation,
this technique exploits the hypersensitivity to MMC that characterizes FA cells. In
brief, cells belonging to a known complementation group are transfected with an
episomal cDNA expression library. After selection for stable transformants, cells are
treated with MMC essentially eliminating all cells that have not taken up the proper
cDNA that functionally restores the FA biochemical pathway. After expansion of
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these corrected cells, the episomally replicated plasmid can be extracted and
analyzed by DNA sequencing.
     This complementation cloning technique has proven to be highly successful and
resulted in the identification of FANCA, -C, -E, -F, and -G genes that correspond to the
complementation groups A, C, E, F, and G respectively [18–22]. In addition to the
complementation cloning technique, conventional positional cloning resulted in
identification of FANCA (independent of the complementation cloning of this gene)
and FANCD2 [23, 24]. Moreover, a candidate gene approach resulted in the
discovery of FANCD1 (which is identical to the breast cancer susceptibility gene
BRCA2). The identification of FANCL, and very recently the identification of FANCB
were based on protein association studies [25–27]. At present, the putative FANCI
and FANCJ genes remain to be found. Very recently and after this thesis was
completed, the novel complementation group FA-M, its corresponding FANCM
gene, as well as the FANCJ gene were identified [28–30].
The FA biochemical pathway
With the identification of most of the FANC genes it became possible to study the
FANC gene products and their role in the FA biochemical pathway. Compelling
evidence has been accumulated that most of the FANC proteins, FANCA, -B, -C, -E, -
F, -G, and -L, assemble in a nuclear multisubunit protein complex, termed the FA
core complex. Direct interactions have been shown between FANCA and FANCG
[31–33], between FANCF and FANCG [34–36], and between FANCC and FANCE [34,
37]. Although some cytoplasmic subcomplexes may be present, the largest FA core
complex resides in the nucleus and has a size of 1–2 MDa [26, 27, 38–42].
Furthermore, several currently unknown components of the complexes remain to
be identified, as shown in experiments by Meetei et al. [43].
     The presence of a functional FA core complex is essential to activate the
downstream FANCD2 protein by monoubiquitylation of Lys561 [44]. In contrast to
polyubiquitylation, which targets a protein for destruction by the proteasome,
monoubiquitin is a regulator of the location and activity of a diverse set of proteins
[45]. In all FA patient-derived cells, except those from FA-D1 and FA-J
complementation groups, this monoubiquitylation of FANCD2 is absent. Functional
correction of these cell lines by transfection with the corresponding cDNAs restores
the monoubiquitylation and the sensitivity to DNA cross-linking agents returns to a
wild type level. Since it has been shown that FANCE directly interacts with FANCD2
[35, 37], this protein may physically link the FA core complex to FANCD2 to enable
its monoubiquitylation. Except for FANCL, none of the core complex subunits
harbors a catalytic domain and the RING domain of FANCL is expected to be
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involved in this modification of FANCD2 [26, chapter 5 of this thesis]. It has now
widely been recognized that monoubiquitylation of FANCD2 is an essential step in
the FA pathway. In addition, this modification is required for further downstream
reactions, such as the colocalization with BRCA1 in DNA damage induced repair foci
[44]. Moreover, FANCD1/BRCA2 as well as FANCJ are currently hypothesized to
function downstream of FANCD2. The precise role of FANCD1/BRCA2 within the
pathway remains unclear, but it has been shown that this protein directly interacts
with FANCD2 [46, 47].
Function of the FA pathway
Repair of DNA interstrand cross-links – The sensitivity of FA cells to a wide range of
agents that induce DNA interstrand cross-links (ICLs) indicates that the FA pathway
is involved in the repair of this type of DNA damage. Interestingly, ICLs are among
the most toxic types of DNA damage and ICL repair is complicated because both
strands are affected and no complementary strand is available as template for
repair. It has been indicated that both nucleotide excision repair (NER) and
recombinational repair are required for ICL removal and that double-strand breaks
(DSBs) are produced during the process in eukaryotic cells [48]. In Saccharomyces
cerevisiae it has been shown that during psoralen induced ICL repair NER excises the
cross-linked DNA on both strands, producing a DSB intermediate, which is then
repaired through homologous recombination (HR) [49, 50].
     Emerging evidence suggests that the FA pathway of ICL repair may act mainly
during the S-phase of the cell cycle and after DSBs have been formed. The
activation of FANCD2 during S-phase and the S-phase specific colocalization of
FANCD2 with BRCA1 and RAD51 [51] suggests that ICL repair mediated by the FA
pathway may be specific to this phase of the cell cycle. In has been shown that
psoralen-treated primary fibroblasts arrest in the late S-phase regardless of when
the damage was introduced during the cell cycle [52]. During DNA synthesis,
replication forks that encounter an ICL may collapse and induce a cell cycle
checkpoint in order to allow sufficient time to repair the ICL. Moreover, replicative
stress-inducing agents as aphidicolin and hydroxyurea also induce strong
monoubiquitylation of FANCD2 [53].
     Hypersensitivity of FA cells to ICLs is unlikely due to a defect in the initial step of
ICL repair. Pulsed-field gel electrophoresis and single-cell electrophoresis of MMC-
treated cells show that FA cells form DSBs and unhook MMC-induced ICL similarly
as wild type cells [54]. This indicates that the FA pathway may function after the
generation of DSBs has occurred [55]. The colocalization of activated FANCD2 with
the homologous recombination repair proteins BRCA1 and RAD51 [51] as well as
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FANCD1 being identical to BRCA2 [25] suggests that these generated DSBs may be
repaired through homologous recombination. However, as recently suggested by
Nakanishi et al. [56] the FA pathway may – besides its role in promoting homology-
directed repair of DSBs – also promote single-strand annealing which is a
alternative route for repair of DSBs.
Other functions of the FA pathway – Previous research has indicated that the FANC
proteins may have additional functions. Primary FA cells show a marked sensitivity
to a non-physiologically high level of oxygen resulting in chromosomal breakage
[57] and arrest in the G2 phase of the cell cycle [58], in contrast to wild type cells.
Another study shows that Fancc–/– Sod1–/– double knockout mice have hematopoietic
deficiency but not Fancc–/– and Sod1–/– single knockouts [59]. While this does not
necessarily indicate a direct role of the FA pathway in oxygen metabolism, it may
indicate that metabolically generated oxygen radicals may be more toxic to FA cells
than to wild type cells.
     The FANCC protein has been shown to interact with NADPH cytochrome P450
reductase, the transcription factor STAT1, and glutathione S-transferase P1-1 [60–
62], suggesting multiple functions for this protein. In addition, extensive yeast two-
hybrid (Y2H) screening has identified 69 different interactors of FANCA, FANCC, and
FANCG, including DAXX, Ran, IκBγ, USP14, SNX5, and FAZF [63]. Most of these
interacting proteins are associated with transcription regulation, signaling,
oxidative metabolism, and intracellular transport. However, while the FA core
complex purification method by Meetei et al. [43] has proven its applicability
resulting in the identification of three novel FANC genes (FANCB, FANCL, and
FANCM) the reliability of the Y2H dataset is still remaining obscure and may contain
false positives.
Animal models for FA
Since the FANC genes are conserved throughout vertebrate evolution, several
animal models have been used to study Fanconi anemia. Fanca–/–, Fancc–/–, Fancg–/–,
Fancl/Pog–/–, and Fanca–/–/Fancc–/– mutant mice show no developmental
abnormalities, bone marrow failure or cancer proneness but do show a decreased
fertility, spontaneous chromosomal instability at the cellular level and
hypersensitivity to DNA cross linking agents [64–70]. In contrast, Fanconi anemia
complementation group D2 knockout mice have been reported to show a more
severe phenotype including microphthalmia, perinatal lethality, and epithelial
cancers [71]. The chicken B cell line DT40 has also been used for studying the FA
biochemical pathway and Fancg–/–, Fancc–/–, and Fancd2–/– knockout DT40 cells have
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been reported [72–74]. These chicken cells show increased sensitivity to DNA cross
linking agents and exhibit increased MMC and radiation-induced chromosomal
breakage. Finally, Liu et al. [75] showed that downregulation of Fancd2 during
zebrafish embryogenesis caused defects similar to those found in FA such as
growth retardation, microcephaly, and microopthalmia.
Aim and outline of this thesis
Although the majority of the FANC genes have been identified to date, still little is
known about the biochemistry of the FA pathway and how it is involved in ICL
repair. While most other protein sequences contain conserved domains providing
clues for their biochemical function, the FANC proteins are all ‘orphans’ showing no
homology to other proteins making a prediction about their function difficult. In
addition, the very limited conserved FANC proteins have no homologs in important
model species such as Escherichia coli and yeast in which ICL repair pathways have
been studied in great detail.
     The aim of this thesis was to study the FANC proteins in evolutionary distantly
related species, e.g. chicken, clawed frog, fish, and fruit fly. Amino acids that are
conserved between these species may be functionally important and could
potentially provide clues about the molecular action of the FANC proteins.
     In chapter 2 the principle of orphan gene products, protein domains, and
evolutionary conservation is further explained. In this chapter, it is discussed how a
bioinformatic approach could provide important information about the
biochemical function of a protein. In a preliminary analysis, evidence was found that
FANCG contains at least 2 tetratricopeptide repeat (TPR) motifs. The FANCG
sequence was further studied in chapter 3 and a total of 7 TPRs were identified. The
TPR motif is a protein-protein interaction domain and TPR-containing proteins
often function as scaffolds mediating the assembly of multisubunit protein
complexes. The importance of the TPRs in FANCG was studied by mutational
analysis which confirmed that the TPRs function as protein-protein interaction
modules and are required for a functional FA pathway. In chapter 4, the FANCF
sequence was studied but no protein domain was identified. Extensive mutational
analysis suggests that this protein functions as an important adaptor molecule
within the FA core complex. All other FANC protein sequences were also examined
(chapter 5) and some evidence was obtained that FANCA and FANCC may contain
HEAT repeats. Similarly as for the FANCG protein, FANCA and FANCC may function
as scaffolds in the assembly of the FA core complex. Furthermore, FANCD2 may be a
myosin heavy chain-like molecule. Careful analysis of FANCL revealed that it does
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not contain a PHD domain – as previously suggested by others [26] – but a RING
domain required for its ubiquitin ligase activity.
     Since in non-vertebrates such as the fruit fly Drosophila melanogaster the FA core
complex subunits are absent, it was not possible to study their sequences in these
species. However, the recent identification of FANCL, which – in contrast to the
other FANC core complex subunits – is also present in the fruit fly genome, allowed
dissection of the putative FA pathway in this species and in chapter 6 the first
preliminary data are presented.
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C H A P T E R
2
Evolutionary clues to the
molecular function of
Fanconi anemia genes
anconi anemia (FA) is an autosomal recessively inherited disease with diverse
clinical symptoms including developmental anomalies, predisposition to
neoplasia, and a deficiency of hematopoietic stem cells resulting in progressive
aplastic anemia. FA is genetically heterogeneous with at least 8 genes being
implicated on the basis of functional complementation studies. To date, six FA
genes are known: FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG, all of which
encode orphan proteins sharing no homology to each other nor to any other
known protein. In addition, they do not appear to possess any domains with
homology to currently known protein domains, which makes a prediction about
their molecular action difficult. Studying the molecular evolution of FA genes and
their products using sensitive database search methods such as PSI-BLAST may
provide novel insight into the nature of the FA pathway and its relationship to
hematopoiesis, embryonic development and the origin of malignancies. Preliminary
results of such an approach show that at least one FA protein, FANCG, may contain
a known domain, suggesting that this protein is a member of the family of
tetratricopeptide repeat-containing proteins.
Eric Blom, Henri J. van de Vrugt, Johan P. de Winter,
Fré Arwert & Hans Joenje
Acta Haematol 2002; 108: 231–236
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Introduction
Fanconi anemia (FA) is a rare autosomal recessive disorder characterized by
multiple congenital anomalies, progressive bone marrow failure, and cancer
predisposition, especially acute myeloid leukemia (AML) and squamous cell
carcinomas [1, 2]. Cells derived from FA patients show spontaneous chromosomal
instability and a characteristic hypersensitivity to DNA cross-linking agents, such as
mitomycin C and diepoxybutane [3, 4]. With at least eight distinct disease genes
predicted from somatic cell hybridization studies, FA is genetically highly
heterogeneous [5–7]. To date, six FA genes have been cloned [8–14], but little is
known about the molecular action of their gene products (table 1). All FA genes
encode orphan proteins that share no homology to each other nor to any other
known protein. In addition, no functional domains have so far been detected in
these proteins, making a prediction about their molecular function difficult. In
normal cells, the FA proteins FANCA, FANCC, FANCG, and FANCF assemble in a
multi-subunit nuclear core complex [15–18], which suggests that protein-protein
binding domains may be detectable within these proteins. The FA protein core
complex, however, fails to be formed in cell lines derived from complementation
groups B and E, suggesting an upstream action for the FANCB and FANCE proteins
in the FA pathway [19].
     Recently, the FANCD2 gene was cloned [14] and appears to encode yet another
orphan protein. Unlike the other FA proteins, FANCD2 is conserved in
nonvertebrate animals, such as Drosophila melanogaster and even in the plant
Arabidopsis thaliana, indicating that the FA pathway may be conserved throughout
eukaryote evolution. In the presence of a functional FA protein core complex, the
FANCD2 protein is activated to a monoubiquitinated isoform that accumulates in
nuclear foci in response to DNA damaging agents and colocalizes with the breast
cancer susceptibility protein BRCA1 [20].
     Since during evolution new proteins typically arise via gene duplication or exon
shuffling [21], it seems very unlikely that FA proteins are without any similarity to
other proteins. In gene duplication, the complete gene is duplicated, after which
one copy retains its original function whereas the other copy is available for
acquiring a new function by the process of random mutagenesis or exon shuffling
in combination with selection. Alternatively, the duplicated gene may become
inactivated, e.g. by a stop codon, and as a result this gene may remain in the
genome as a pseudogene. For example, myoglobin as well as the α- and β-families
of hemoglobin have all arisen from one ancestral gene, while also several
pseudogenes are present in the human genome. Evolution via exon shuffling
occurs when a new exon is inserted into an existing gene or when an exon is
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duplicated within the same gene. Since exons often represent functional protein
domains (regions that perform a specific function), acquisition of a new exon could
enhance protein function. Tissue-type specific plasminogen activator is an example
of a protein that is composed of different functional domains. It contains a finger
domain, a growth factor domain, two kringle domains and an enzymatic serine
protease domain and is therefore a good example of a mosaic protein, which has
presumably arisen by exon shuffling.
     Finding similarities between proteins can be an important starting point for the
prediction of molecular function, which can then be experimentally tested.
However, the recently identified FA proteins: FANCA, -C, -D2, -E, -F, and -G are all
unique proteins that lack statistically significant similarities to any of currently
known protein domains making predictions about their molecular function difficult.
One strategy to bypass this obstacle could be to study the evolutionary
conservation among different species and subsequently applying sensitive database
search methods in order to identify functionally important domains. Such a strategy
would require first that orthologs of FA genes in nonmammalian species, such as
fish and Xenopus, are determined. Orthologs are genes that originated from the
same ancestral gene at an earlier evolutionary time and are likely to perform the
same or a similar function. A multiple alignment is then prepared of these
orthologous sequences after which a specific rather than a standard score model is
utilized for the protein in question. For each position, each amino acid is given a
score depending on how likely it is to occur. This scoring model can then be used
for searching the database for similarities in a more sensitive way than the BLAST
algorithm. PSI-BLAST (position-specific iterated blast) is an example of a program
that is easy to use and applies a position-specific scoring matrix. It performs an
iterative search in which sequences found in one searching round are used to build
a score model for the next round. We applied this approach focusing on the FANCG
protein, which appears to be conserved in the zebrafish. Searching the
nonredundant database at NCBI with the C-terminus of zebrafish Fancg using PSI-
BLAST revealed a previously unknown similarity to a putative mouse and a
Drosophila protein. This similarity is most likely based on the presence of one or
more tetratricopeptide repeats (TPRs) [22, 23] in the C-terminus of FANCG. The TPR
is a degenerate 34-amino-acid repeated motif with only few loosely conserved
consensus residues and is thought to mediate protein-protein interaction. The
presence of one or more TPR motifs in the C-terminus of FANCG may be responsible
for its interaction with other proteins in the FA protein core complex.
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Materials and methods
Database searches were performed using the BLAST and PSI-BLAST algorithms [24]
at the National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.
nih.gov/BLAST/) using the protein sequences of the cloned FA genes as queries. In
general, BLAST searches via a protein sequence (i.e. protein to protein database by
blastp, nucleotide to protein database by blastx, or protein to nucleotide database
by tblastn) are more sensitive than a nucleotide query to nucleotide database
(blastn) because they avoid the problem of (functionally silent) sequence
divergence due to codon degeneracy. In addition, decreasing the word size
parameter from 3 to 2 tends to enhance sensitivity. Identification of possible
domains was investigated using Pfam 6.4 (May 2001, 2866 models) [25] at
http://pfam.wustl.edu/. Pfam is a collection of multiple alignments and profile
hidden Markov models (HMMs) of protein domain families. Protein sequences can
be searched against these profile HMMs to locate regions of the sequence that
belong to domain families. Multiple alignments were prepared by using the
ClustalW (www.ebi.ac.uk/clustalw/) and Boxshade (www.ch.embnet.org/software/
BOX_form.html) programs.
Results and discussion
Evolution of FA Proteins – Between mouse and human FA proteins, only 55–80% of
amino acids have remained identical during evolution (table 1). This percentage is
further decreased with greater evolutionary distance, such as for human-Xenopus
and human-fish (Fig. 1). Searching for homologs in nonvertebrate species, such as
D. melanogaster, has failed, however. This indicates that apparently too few amino
acids have remained identical between human and Drosophila to result in a
statistically significant BLAST hit, or that FA proteins just do not exist in lower
species. An interesting exception is the FANCD2 protein, which is conserved in
Caenorhabditis elegans, D. melanogaster and even plants (A. thaliana), which
indicates that at least one FA protein was preserved during evolution. Since FA
proteins are thought to function in one pathway, why is this particular FA protein
more conserved than the others? Perhaps FANCD2 plays a role in a more ancient
pathway on which, later in evolution, the action of the non-D2 proteins has been
superimposed. In this scenario, a new regulatory mechanism for FANCD2 activity
might have developed during vertebrate evolution. Alternatively, non-D2 proteins
do exist in nonvertebrates, but due to their low level of amino acid conservation are
undetectable, which essentially means that their BLAST scores do not reach
statistical significance.





















Fig. 1. Phylogenetic relationships of several model species (boxed) commonly used for biomedical research.
From these species, complete genome sequences or at least EST sequences, are available that can be used
for studying the evolution of the FA proteins. Evolutionary conservation of FA proteins appears to be limited
to the chordata. However, the FANCD2 protein is conserved in metazoa and in the plant A. thaliana,
indicating that at least part of the FA pathway may be conserved in all eukaryote species.
     Secondary structure (distribution of α-helices and β-sheets in a protein) and
tertiary structure (overall 3D structure of the protein) are generally more preserved
than primary structure (amino acids), indicating that many amino acid substitutions
do not change the global 3D structure of the protein and therefore do not alter
protein function. This is proven by the fact that cDNAs encoding mouse Fanca,
Fancc, and Fancg [26–28, H.J. van de Vrugt, unpubl. data], are all able to
complement the corresponding human FA cells, despite an amino acid sequence
identity of only 62–72% with the human sequence. Research to identify non-D2
homologues in nonvertebrates, such as Drosophila, should focus on database
search algorithms, such as PSI-BLAST and Profile searching, which are more
sensitive than the commonly used BLAST algorithm. Here, we describe preliminary
results obtained by this approach applied to the FANCG protein.
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Table 1. FA genes and their products











FANCA 16q24.3 43 163 1455 ~70 Fish 66
FANCB unknown - - - rare - -
FANCC 9q22.3 14 63 558 ~10 Fish 62a
FANCD1 unknown - - - rare - -




FANCE 6p21.3 10 60 536 rare Fish 65
FANCF 11p15 1 42 374 rare Fish ~55b
FANCG 9p13 14 70 622 ~10 Fish 72
a The mouse sequence contains an extra exon. For comparison: identity human-rat is 66%.
b This is an estimation based on EST sequences in the NCBI database.
FANCG Shows Homology to the TPR Motif – The FANCG protein appears to be
conserved at least down to the ray-finned fishes. Searching the NCBI EST_others
database [which includes expressed sequence tags (ESTs) derived only from non-
mammalian species] using BLAST revealed a weak but significant similarity (E-value
∼1⋅10–4, word size parameter set at 2 rather than 3) with a zebrafish EST clone
(Acc.No. BG302995), which represents the C-terminus of FANCG (Fig. 2). In order to
determine whether a BLAST hit is significant, the algorithm calculates an Expect
value (E-value). The Expect value (E) is a parameter that describes the number of hits
one can expect just by chance when searching a particular database, thus providing
an estimate of whether a hit is significant or not. When the protein sequence of this
zebrafish EST is used as a query in a PSI-BLAST search, the human FANCG is
detected in the first iteration and is then used for creating a position-specific score
matrix. In the second iteration, a weak but significant similarity with a putative
mouse protein (Acc.No. BAB28115, E = 1⋅10–4) was found and in the third iteration a
putative Drosophila protein CG6621 (Acc.No. AAF54579, E = 6⋅10–7). This indicates
that at least part of the FANCG protein must also be present in other proteins. This
similarity between these proteins is most likely based on the presence of one or
more TPRs in these proteins (Fig. 3). In all these proteins, a TPR motif is predicted by
Pfam. The TPR motif is present in a wide variety of proteins including e.g. the
subunits cdc16, cdc23, and cdc27 of the multiprotein E3 ubiquitin ligase ‘anaphase
promoting’ complex (APC), several transcription factors, the PKR protein kinase
inhibitor, and peroxisomal as well as mitochondrial import proteins [22, 23]. It is
usually present in tandem arrays of 3–16 motifs suggesting that FANCG may
contain several such motifs. Sequencing the full length zebrafish Fancg gene may
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help to pinpoint the exact locations of additional TPR motifs in human FANCG.
Indeed, Pfam predicts an additional TPR motif in zebrafish Fancg C-terminus
immediately downstream of the first one, but not in the human sequence. An
additional TPR motif is predicted at position 246–279 in the human protein, while in
both the mouse and Drosophila putative proteins a total of three repeats are
predicted. It should be noted that both putative mouse and Drosophila proteins are
not homologs of FANCG, but like FANCG, are predicted to contain several TPR
motifs.
     Tandem arrays of TPR motifs are thought to be involved in the assembly of
multiprotein complexes, suggesting that TPR motifs in FANCG may play a role in the
assembly of the FA protein core complex. Clinical evidence for the importance of
this motif at position 514–547 in FANCG comes from the identification of two
pathogenic missense mutations in this region [29]. The TPR motif is 34 amino acids
long with only few loosely conserved residues (Fig. 3) that are conserved in terms of
their size, hydrophobicity and spacing. The missense mutation G521E [29] alters a
conserved glycine residue and presumably disrupts the TPR motif (Fig. 3). In
addition, Nakanishi et al. [29] showed that this mutant protein is not detectable by
immunoblotting suggesting that the protein or mRNA is unstable. Missense
mutation G546R is expressed at normal levels, but fails to correct the cellular defect
of FA-G cells, which confirms that this motif may be important for the function of
FANCG.
Zebrafish Fancg homolog KGPALAGRGLCFLERGQLKEALRDLHLGLQMSPGCKNTEMWLAEVLWRLDRREEALAHWR
Human FANCG C-term. (513-572) RAAALISRGLEWVASGQDTKALQDFLLSVQMCPGNRDTYFHLLQTLKRLDRRDEATALWW
Zebrafish Fancg homolog --EAHSISDRPKSIK-LPLFLQAWAEETAFDFSDLNKKMEEYIQAKNA----
Human FANCG C-term. (573-622) RLEAQTKGSHEDALWSLPLYLESYLSWIRP--SDRDAFLEEFRTSLPKSCDL
Fig. 2. Alignment of human FANCG and zebrafish Fancg homolog. Zebrafish sequence was derived from
NCBI BG302995 entry (EST sequence). Since the full-length zebrafish sequence is not available yet, only the C-
terminal region is shown. Alignment was prepared by using the Boxshade program.
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         *                        *
Human FANCG (514-547)              AAALISRGLEWVASGQDTKALQDFLLSVQMCPGN
Zebrafish Fancg homolog (C-terminus) GPALAGRGLCFLERGQLKEALRDLHLGLQMSPGC
Mouse putative 2700016E08 gene (234-267) VEALVARGALYATKGSLNKAIEDFELALENCPTH
Drosophila CG6621 gene product (336-369) VEALVARGALYANRGSFLKGLQDFEKALHLNKYH
Consensus TPR by Pfam aeayynlGnaylklgkydeAiedyekALeldPnn
Fig. 3. Comparison of putative TPR motifs in human FANCG, zebrafish Fancg homolog (sequence derived
from a EST sequence, NCBI entry BG302995), mouse putative 2700016E08 gene (Acc.no. NP_080254 or
BAB28115), and Drosophila CG6621 gene product (Acc.no. AAF54579). In all proteins, a TPR motif is predicted
by Pfam with an expected value above the trusted cut-off value. *Note that G521E is a pathogenic mutation
in human FANCG which presumably destabilizes the protein or mRNA [29]. In addition, the G546R missense
mutation is expressed at normal levels, but fails to complement FA-G cells [29]. Alignment was prepared by
using the Boxshade program.
Conclusion
We conclude that using database search algorithms such as PSI-BLAST may be a
useful approach to classify FA gene products into known protein families.
Preliminary data show that at least one FA protein, FANCG, appears to contain a
known domain, indicating that this protein is a member of the TPR-containing
family of proteins. Since for this approach sequence information for vertebrate
orthologs of the FA proteins is required, research should first focus on the cloning
and sequencing of these orthologs. Fish and Xenopus deserve priority, because
genomic or EST sequence data are already available which is likely to facilitate the
cloning of the cDNAs. In addition, fish and Xenopus are much less related to humans
than for example rodents or other mammals, and thus will provide a more stringent
screen for evolutionary conservation.
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C H A P T E R
3
Multiple TPR motifs characterize the
Fanconi anemia FANCG protein
he genome protection pathway that is defective in patients with Fanconi
anemia (FA) is controlled by at least eight genes, including BRCA2. A key step in
the pathway involves the monoubiquitylation of FANCD2, which critically depends
on a multi-subunit nuclear ‘core complex’ of at least six FANC proteins (FANCA, -C, -
E, -F, -G, and -L). Except for FANCL, which has WD40 repeats and a RING finger
domain, no significant domain structure has so far been recognized in any of the
core complex proteins. By using a homology search strategy comparing the human
FANCG protein sequence with its ortholog sequences in Oryzias latipes (Japanese
rice fish) and Danio rerio (zebrafish) we identified at least seven tetratricopeptide
repeat motifs (TPRs) covering a major part of this protein. TPRs are degenerate 34-
amino acid repeat motifs which function as scaffolds mediating protein–protein
interactions, often found in multiprotein complexes. In four out of five TPR motifs
tested (TPR1, -2, -5, and -6), targeted missense mutagenesis disrupting the motifs at
the critical position 8 of each TPR caused complete or partial loss of FANCG
function. Loss of function was evident from failure of the mutant proteins to
complement the cellular FA phenotype in FA-G lymphoblasts, which was correlated
with loss of binding to FANCA. Although the TPR4 mutant fully complemented the
cells, it showed a reduced interaction with FANCA, suggesting that this TPR may
also be of functional importance. The recognition of FANCG as a typical TPR protein
predicts this protein to play a key role in the assembly and/or stabilization of the
nuclear FA protein core complex.
Eric Blom, Henri J. van de Vrugt, Yne de Vries,
Johan P. de Winter, Fré Arwert & Hans Joenje
DNA Repair 2004; 3: 77–84
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Introduction
Fanconi anemia (FA) is a chromosomal instability syndrome characterized by
developmental abnormalities, progressive pancytopenia and cancer-proneness [1].
The cellular phenotype is characterized by occurrence of spontaneous
chromosomal aberrations and a hypersensitivity to agents that generate DNA
crosslinks, such as mitomycin C (MMC) and diepoxybutane. Cell fusion studies
revealed that FA is genetically heterogeneous with at least eleven
complementation groups (A, B, C, D1, D2, E, F, G, I, J, and L) ([2–5]; Levitus et al.,
submitted for publication). At present, six FA genes have been identified by
complementation cloning or by positional cloning techniques: FANCA, -C, -D2, -E, -F,
and -G [2, 6–11], while a candidate-gene approach has led to identification of the
breast cancer susceptibility gene BRCA2 as the gene defective in FA-D1 patients
[12]. The most recent FA gene discovery (FANCL) followed identification of a novel
43 kD WD40 repeat/RING finger protein that was associated with the nuclear FA
protein core complex [5].
     The nuclear core complex consists of at least six FA gene products (FANCA, -C, -E,
-F, -G, and -L) [5, 13–17] and is required for the activation of FANCD2 by
monoubiquitylation at Lys561 [18]. This modification is a key step in the pathway
allowing further downstream reactions to take place, such as the association of
FANCD2 with BRCA1 in nuclear repair foci. Both FANCD2 as well as FANCL are
conserved in Drosophila melanogaster, but none of the other FANC proteins seem to
exist in this organism [19, 20]. This suggests that at least a partial FA pathway is
likely to be present in Drosophila and that the multi-protein core complex, found in
vertebrates only, may have arisen later during evolution.
     Here, we present the domain structure of FANCG. Although the core complex
proteins FANCA, -C, -E, -F, and -G have been known for several years, no functional
clues have yet been derived from their amino acid sequences. These proteins are
only present in vertebrates and show no significant homology to other proteins,
making their domain structure enigmatic. Previously, a putative peroxidase domain
has been claimed in FANCA, but several amino acid substitutions that critically alter
the consensus sequence had no effect on activity [21]. In addition, in FANCF a
domain was reported that showed homology to the prokaryotic RNA binding
protein ROM [9], but this homology is not preserved in the Xenopus laevis ortholog
[Léveillé et al., manuscript in preparation] indicating that this motif is of no
functional significance either. In order to elucidate the domain structure of FANCG,
we identified and sequenced the zebrafish (Danio rerio) and the Japanese rice fish
(Oryzias latipes) FANCG orthologs and analyzed them using a bioinformatic strategy.
A preliminary report outlining the details of this approach has been published
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previously [20]. In this study, we show that FANCG is composed of at least seven
tetratricopeptide repeats (TPRs), together covering a major part of the protein. The
TPR repeat is a highly degenerate 34-amino acid motif, typically present in tandem
arrays of 3–16 motifs per protein. Each TPR motif is composed of a pair of anti-
parallel α-helices of equal length and multiple TPRs fold the protein into a right-
handed superhelical structure, which forms a scaffold for protein–protein
interactions [22, 23]. Disturbance of individual TPRs by mutagenesis revealed that at
least four TPRs are critical for the function of FANCG as assessed by the functional
complementation of the cellular phenotype in FA-G cells. In addition, these TPRs are
required for interaction with FANCA, confirming that they act as protein–protein
interaction motifs. In conclusion, the presence of multiple TPRs in FANCG suggests
an essential role for FANCG in the assembly and/or stabilization of the FA protein
core complex.
Materials and methods
Constructs – An EST clone containing full-length Danio rerio (zebrafish) fancg cDNA
was obtained from RZPD (Deutsches Ressourcenzentrum für Genomforschung,
Germany, clone IMAGp998A239112Q2) and sequenced (GenBank acc. no.
AJ496390). An Oryzias latipes (Japanese rice fish) EST clone containing full-length
fancg cDNA (clone name MF01SSA194A05) was a kind gift of Yumiko Saga (National
Institute of Genetics, Japan) and was also sequenced (GenBank acc. no. AJ566763).
FANCG mutant constructs containing HA-tagged human FANCG cDNA in the
episomal mammalian expression vector pMEP4 (Invitrogen) were generated using
standard PCR mutagenesis methods. All mutant PCR fragments were amplified
using Platinum Pfx DNA proofreading polymerase (Invitrogen) and sequenced in
full-length to confirm the presence of the intended mutation and the absence of
other mutations.
Bioinformatic analysis – Danio rerio and Oryzias latipes fancg protein sequences were
analyzed as previously described [20] and as outlined in the results section.
Cell culture and transfection – EUFA316 (FA-G) lymphoblastoid cells were grown in
RPMI 1640 medium (Gibco-BRL) supplemented with 10% fetal bovine serum (Gibco-
BRL) at 37°C under an atmosphere of 5% CO2 in air. To stably transfect cells, 4 × 106
exponentially growing cells were electroporated (BTX Electro Square Porator
ECM830) with 10 µg plasmid DNA (QIAfilter Plasmid Midi kit, Qiagen) and the
transfected cells were then selected for 3 weeks in medium supplemented with 100
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µg/ml Hygromycin B (Roche Molecular Biochemicals). Cells carrying the pMEP4
vector were grown in the presence of 40 µM Zn2+ to induce transcription from the
metallothionein promoter. This concentration of Zn2+ had no effect on cell growth.
MMC-induced growth inhibition test – To test functional complementation of the
TPR-mutated FANCG constructs, stably transfected EUFA316 cells were exposed to
0, 1, 2, 3, 6, 10, 30, 60, and 100 nM mitomycin C (Kyowa Hakko Kyogo Co., Ltd.,
Japan) in parallel cultures for several days (approximately three population
doublings), after which the percentage growth was determined using a Coulter
counter, as described previously [24].
Coimmunoprecipitation and immunoblotting – Total cell extracts were prepared by
lysis of 5 × 106 cells in 0.5 ml lysis buffer (50 mM Tris–HCl pH7.4, 150 mM NaCl, 1%
Nonidet P40, 500 µg/ml Pefabloc, 1 µg/ml apoprotinin, 1 µg/ml pepstatin, 1 µg/ml
leupeptin) for 10 min, on ice. Lysates were sheared through a 19-gauge needle,
then clarified by centrifugation (14,000 rpm, 4°C) in a microcentrifuge, after which 2
µl of α-HA antibody (12CA5 mouse monoclonal, Boehringer Mannheim) was added
and incubated at 4°C, overnight. Antibody-bound proteins were collected with 40
µl protein A agarose beads (Invitrogen) for 30 min at 4°C and washed three times in
lysis buffer, after which samples were analyzed by immunoblotting.
     For immunoblotting, 20 µl of 2× sample buffer (30 mM Tris–HCl pH 6.8, 0.8%
sodium dodecyl sulfate (SDS), 5% 2-mercaptoethanol, 4% glycerol, 0.4%
bromphenol blue) was added and samples were boiled for 5 min. After
centrifugation, the supernatant was subjected to standard 8% polyacrylamide SDS
gel electrophoresis after which proteins were transferred to an Immobilon-P
transfer membrane (Millipore) in transfer buffer (25 mM Tris–HCl, 200 mM glycine,
15% methanol) at 300 mA, at 4 °C for 2 h. The membrane was blocked for 30 min in
5% non-fat dry milk in TBST (10 mM Tris–HCl, 150 mM NaCl, 0.1% Tween-20),
washed in TBST, and incubated with primary antibody (α-HA 12CA5 or α-FANCA
Rb89) in 2% non-fat dry milk/TBST, overnight at 4°C. After washing three times in
TBST, the membrane was incubated in secondary antibody (goat anti-mouse-HRP or
goat anti-rabbit, DAKO, Denmark) in 2% non-fat dry milk/TBST for 1 h, at room
temperature. The membrane was then washed five times in TBST and developed by
using the ECL Western blotting analysis system (Amersham Pharmacia) according to
manufacturer’s instructions.
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ol fancg 1   -----MNQQQSLFDYWTEENNELVRNCKEGQNA--VGP------HLTSGFQKLLRKIQGV
dr fancg 1   -----MSVIPCLVDRWSEENNNIILAWKQNEQS--LQPNREVRKRCYSESLKLLQKTQGL
h FANCG 1   MSRQTTSVGSSCLDLWREKNDRLVRQAKVAQNSGLTLRRQQLAQDALEGLRGLLHSLQGL
ol fancg 48  PPETDHAQLELSVVYNACICLISQSQ--FTEAELLLKQATERILQMKGE--NLCQSDAPI
dr fancg 54  PAATERLKLELTVSYNTCLFALVFSN--PSEMEESLTRSLFRALEAADC--PVSSTEPVK
h FANCG 61  PAAVPVLPLELTVTCNFIILRASLAQGFTEDQAQDIQRSLERVLETQEQQGPRLEQGLRE
ol fancg 104 LWITAIRS-VENTALHPFLLLLPCLQWAIWLATCQLKPIKDFQESSMFEALSSG----VG
dr fancg 110 LWEDALRT-FGCSVYLPYVHKLLLLQWMLWLMQGQLERVLTLLTQIDSKRECSAPVNLQT
h FANCG 121 LWDSVLRASCLLPELLSALHRLVGLQAALWLSADRLGDLALLLETLN-GSQSGASKDLLL
ol fancg 159 GDCGEDAKETSTKVPLLVMDPKRFTELLQICRVIVQSAEQMNEGRSSEALPLLQAASKLP
dr fancg 169 ETRNLPLRLEEDTSLMVAMAAKDLKELLHICTVICQGVEQMKTEKYSEALAVFQEAKGLP
h FANCG 180 LLKTWSPPAEELDAPLTLQDAQGLKDVLLTAFAYRQGLQELITGNPDKALSSLHEAASGL
ol fancg 219 APKTLVAYTHLLSGSCLAHMNCPQMALHCYKKALETDAQCVYALHQSTLVYCELGNTQAE
dr fancg 229 SPRSLLAHIHTLTGQTFAKLDQPHCALHYYRKALEVDFSCLGALYQSALVFRQLGNPKAE
h FANCG 240 CPRPVLVQVYTALGSCHRKMGNPQRALLYLVAALKEGSAWGPPLLEASRLYQQLGDTTAE
ol fancg 279 IQALHIMHSTLLLPSPAEPSTAGVQLLSPSLLLGSQSLKDLLSVPSALSVLHRLALKCIL
dr fancg 289 MEALHLLYSAVQLQS--DKSLSSFSLVSPAMLLGGEQMSFISRVPSPSLILHTLANTCVL
h FANCG 300 LESLELLVEALNVPCS---SKAPQFLIEVELLLPPPDLASPLHCGTQSQTKHILASRCLQ
ol fancg 339 SGRVSEGVKHYLDLLATLHSEDHHRVKVHSEFSTLPRLPKLYLEAAVALLMAQRPADSMA
dr fancg 347 NGSISDGVECYLDLLTSLRSDGKGLVPTENG-TCFPRIPVVYIEAGFALLKAQRYRDALV
h FANCG 357 TGRAGDAAEHYLDLLALLLDSSEPRFSPPPS-PPGPCMPEVFLEAAVALIQAGRAQDALT
ol fancg 399 LCMEVVDSTLELLPETVVIEEPEEGSEAMQKEGEDRIAALLWAAAAYLLQGQCYSQLKDW
dr fancg 406 VCEEVITSTLDFIPERLLLDAAEKQHLADSDAVLENMDFVLWAGAARLLQAQAHWKLKDT
h FANCG 416 LCEELLSRTSSLLPKMSRLWEDAR------KGTKELPYCPLWVSATHLLQGQAWVQLGAQ
ol fancg 459 KQAVTHYTRCVNMLVKVHFKRRDAQTDVSQAGRHLSQTANLHILQRLKGLSLAGRGISFS
dr fancg 466 KEAITHFTRAINQLVKVFVKQKDWK--EKHPGNSEVMVDKVSTLETAKGHALAGRGLCFL
h FANCG 470 KVAISEFSRCLELLFRATPEEKEQG----AAFNCEQGCKSDAALQQLRAAALISRGLEWV
ol fancg 519 QMDHLKEALRDLQLSLQALPEGIGAGLWCGEVLWRLDRKREAAARWEATWSLPT-QSLTE
dr fancg 524 ERGQLKEALRDLHLGLQMSPGCKNTEMWLAEVLWRLDRREEALAHWREAHSISD-RPKSI
h FANCG 526 ASGQDTKALQDFLLSVQMCPGNRDTYFHLLQTLKRLDRRDEATALWWRLEAQTKGSHEDA
ol fancg 578 SFPLYAQEPSFGPLLDSTELRHRIQELGPV-------
dr fancg 583 KLPLFLQAWAEETAFDFSDLNKKMEEYIQAKNAKT--
h FANCG 586 LWSLPLYLESYLSWIRPSDRDAFLEEFRTSLPKSCDL
(a)
Fig 1. Comparative sequence analysis of Oryzias latipes (Japanese rice fish) and Danio rerio (zebrafish)
orthologs with human FANCG. (a) ClustalW alignment of Oryzias latipes, Danio rerio and human FANCG.
Identical residues are indicated in black and similar residues in gray (BoxShade program). The regions
containing the TPR motifs are indicated on top of the sequence. A putative additional TPR, with a low
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FANCG is a member of the family of TPR-containing proteins – We used a
computational approach in our search for possible clues about the domain
structure of FANCG. To ensure maximum sensitivity of the analysis, we compared
the human protein with that of the zebrafish and with that of the Japanese rice fish,
which are both distant orthologs of the human FANCG sequence (Fig. 1a).
Orthologs are genes found in different species that have originated from a common
ancestor gene at an earlier evolutionary time. They help to identify conserved
residues or regions which may be functionally important. Human and zebrafish
show 26% identity and 41% similarity, and human and Japanese rice fish show 24%
identity and 39% similarity. In addition, the two fish sequences share 34% identity
and 52% similarity. Using the two fish orthologs and the PSI-BLAST algorithm [25],
distant but statistically significant homologies were found between FANCG and
several TPR-containing proteins, such as the O-GlcNAc transferase p110 subunit. To
confirm the possible presence of TPRs in FANCG, further analysis was then
performed with the Pfam [26] and REP [27] programs, as a result of which a total of
seven TPR motifs were identified (Fig. 1a). Moreover, region 281–314 (between
TPR2 and TPR3) is likely to contain an additional TPR, but showed less homology to
the TPR consensus sequence. Using a profile search strategy, based on the TPRs
from FANCG (Fig. 1b), the presence of these motifs in other TPR proteins (such as,
cell division control protein cdc27, O-GlcNAc transferase p110 subunit, translocase
of outer membrane TOM70, TPR repeat protein 2, and stress-induced-
phosphoprotein 1 STI1) could correctly be predicted (HMMER and MAST
algorithms). This further confirms the identified motifs as TPRs.
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     Within the seven TPRs, only a few amino acids were found to be conserved in all
(Fig. 1b). Position 8 contains in most cases the small and hydrophobic residues Gly
or Ala, whereas positions 20–21 usually contain Ala-Leu. The TPR motif folds into
two anti-parallel α-helices and these consensus residues are all located at the
interface between the two helices, forming a part of the hydrophobic core of the
motif [23]. Like in other TPR proteins, positions that are outside the consensus
residues are far less conserved.
TPR1, -2, -5 and -6 are critical to the function of FANCG – To investigate the functional
significance of the TPRs, we mutated the conserved 8th position (Gly or Ala) into the
more bulky Gln to disrupt the individual TPRs. Functional activity was then
determined by the ability of the constructs to correct the mitomycin C (MMC)
sensitivity of the FA-G lymphoblastoid cell line EUFA316. All mutants were cloned in
the pMEP4 vector and cells were therefore grown in the presence of 40 µMZn2+ to
induce transcription from its metallothionein promoter. TPR1 (G216Q) showed an
intermediate complementation, but TPR5 (G460Q) and TPR6 (G521Q) showed no
complementation (Fig. 2a), indicating that these three TPRs are required for the FA
pathway to function. In contrast, TPR4 (A401Q) showed a wild type-like phenotype,
suggesting that this motif may not be functionally important. Since the human
FANCG sequence contains no Gly or Ala at position 8 in TPR7 (Fig. 1b), another
missense mutation was chosen that was not at a consensus position (R563E), but
this mutant behaved as wild type making the results for this mutant inconclusive. In
addition, TPR3 was identified only recently after the complementation studies had
been completed and therefore this mutant has not been tested to date. TPR3 was
found using a profile search based on the six previously identified TPRs from all
three species (MAST algorithm).
     Of the mutants studied, only TPR2 (G253Q) showed expression level-dependent
complementation (Fig. 2b). When cells were not grown in the presence of Zn2+, the
promoter activity of the metallothionein promoter is known to be ‘leaky’ resulting
in a much lower, but sufficient expression for full complementation by the wild
type, TPR4 mutant, and TPR7 mutant constructs (Fig. 2b, data not shown for TPR4
and TPR7). However, this was not the case for the TPR2 mutant. This mutant showed
a clear sensitivity to MMC when the promoter was not induced. Since the
uninduced condition may resemble the normal endogenous expression more
closely, we speculate that this mutation might be pathogenic in vivo. These results
show that at least four out of seven TPRs in FANCG are important for a functional FA
pathway.
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Fig 2. Correction of the cellular FA phenotype by TPR-mutated constructs. (a) All constructs were in pMEP4
vector and cells were, therefore, cultured in presence of 40 µM Zn2+ to induce transcription from the
metallothionein promoter. (b) Expression level-dependent complementation of FA-G cells by the TPR2
mutant, but not by other TPR-mutated constructs (data not shown for TPR4-7). Expression of constructs was
verified by Western blotting (data not shown).
TPR1, -2, -4, -5, and -6 are important for interaction with FANCA – Since the TPR motif is
known to be a protein–protein interaction motif, typically present in large protein
complexes, we tested the ability of the TPR-mutants to interact with FANCA, which
is a known direct interaction [28, 29]. TPR1, -2, -5, and -6 mutants showed no
detectable precipitation of FANCA with FANCG (Fig. 3), indicating that a large
region in FANCG is required for this interaction. Although TPR4 mutant still
complemented FA-G cells, the affinity for FANCA appeared to be reduced,
suggesting that this TPR may also be involved in binding to FANCA. The loss of
interaction with FANCA confirms that the TPR motifs in FANCG, like in other TPR-
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Fig 3. Co-immunoprecipitation of FANCG and FANCA. EUFA316 cells were stably transfected with the
indicated HA-tagged pMEP4 expression constructs and cells were treated with 40 µM Zn2+ to induce
transcription from the metallothionein promoter of the vector. Cell extracts were analyzed by
immunoprecipitation with α-HA antibody followed by Western blotting with α-HA and α-FANCA antibodies.
Discussion
This study reveals that FANCG is a member of the family of TPR-containing proteins.
We identified seven TPR motifs covering the majority of the protein. The
tetratricopeptide repeat is a highly degenerate 34-amino acid motif typically
present in tandem arrays of 3–16 motifs per protein. Each TPR is composed of a pair
of anti-parallel α-helices of equal length and the multiple TPRs fold the protein into
a right-handed superhelical structure [30]. This structure forms a scaffold for
protein–protein interaction that is thought to be essential for the assembly of
multiprotein complexes. TPRs have been described in a wide variety of proteins
including the anaphase-promoting complex subunits cdc16, cdc23, and cdc27; hsp-
90-binding immunophilins, peroxisomal and mitochondrial import proteins; the
PKR kinase inhibitor; Strap, a cofactor in the p300 coactivator complex, and XAB2, a
protein involved in transcription-coupled DNA repair and transcription [23, 30–32].
Since TPR proteins are typically present in large protein complexes, the presence of
TPRs in FANCG strongly suggests that FANCG has a role in the assembly and/or
stabilization of the nuclear FA protein core complex. This is in agreement with a
recent three-hybrid study which suggested that FANCG mediates an interaction
between FANCA and FANCF by forming a physical bridge between these proteins
[33].
     We used a mutagenesis approach to assess the functional importance of the TPRs
by creating mutations at their positions 8. Mutations at this consensus position
have been reported to result in a disruption of their function in several other TPR-
containing proteins [34–36]. All mutants that were mutated at their 8th position,
except the TPR4 mutant, were unable to correct the cellular defect in FA-G cells. This
suggests that this consensus position may also be a reporter of function in the
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and the high conservation of the TPR4 region between the two fishes and the
human sequence both indicate that TPR4 may be functionally relevant as well.
Although the human TPR7 sequence contains Leu at its 8th residue and the R563E
mutant complemented FA-G cells as wild type, we speculate that this TPR may still
be a ‘genuine’ TPR. The zebrafish and the Japanese rice fish sequences show strong
homology to the TPR consensus, while between the two fishes and the human
sequence many residues are conserved. Further studies with additional mutants for
TPR4 and TPR7 may help to evaluate the functional relevance for these two TPRs.
     Our results show that most TPRs in FANCG are required for interaction with
FANCA, verifying these TPRs as interaction domains and indicating that a region
spanning at least the residues 209–581 is required for interaction with FANCA. The
interaction between FANCG and FANCA has previously been described as a direct
interaction involving amino acids 18-29 of FANCA [28, 29]. Moreover, several FANCG
deletion studies, all with different results, have been reported. Gordon and
Buchwald recently showed by yeast two-hybrid technique that only a fragment
with a C-terminal deletion of 142 residues is able to interact with FANCA and that
longer C-terminal deletions are not able to interact [33]. In another yeast two-hybrid
study [28], fragments 1-367, 305-622, and 511-622 are all reported to interact with
FANCA, and this is in apparent contradiction with the study of Gordon and
Buchwald. In addition, Kruyt et al. [29] reported that in vitro translated 1-585, 1-550,
and 1-475 fragments are all able to interact weakly by coimmunoprecipitation but
not a fragment spanning 1-400. In tertiary structure, TPRs are known to form a
superhelical structure which forms a groove that mediates interaction with other
proteins. We speculate that fragments of FANCG, as used in these deletion studies,
may only consist of a partial superhelix and may therefore have a reduced affinity
for their substrate. Weak interactions may then only be detected by sensitive
techniques such as the yeast two-hybrid system.
     In conclusion, the FANCG protein appears to lose its previous qualification as an
‘orphan’. At present, FANCG and the very recently identified FANCL protein are the
only ‘upstream’ FANC proteins that have been characterized in terms of their
domain structure. Identification and sequencing of the two fish orthologs have
greatly facilitated the recognition of all TPRs in FANCG. With merely the human
sequence available only three TPRs would have been recognized. In further studies,
the cloning and sequencing of vertebrate orthologs of the other FANC proteins
may, in a similar way, help to elucidate their molecular function.
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The Fanconi anemia gene product
FANCF is a flexible adaptor protein
he Fanconi anemia (FA) protein FANCF is an essential component of a nuclear
core complex that protects the genome against chromosomal instability, but
the specific function of FANCF is still poorly understood. Based upon the homology
between human and Xenopus laevis FANCF, we carried out an extensive
mutagenesis study to examine which domains are functionally important and to
gain more insight into the function of FANCF. In contrast to previous suggestions,
we show that FANCF does not have a ROM-like function. We found that the C-
terminus of FANCF interacts directly with FANCG and allows the assembly of other
FA proteins into a stable complex. The N-terminus appears to stabilize the
interaction with FANCA and FANCG, and is essential for the binding of the
FANCC/FANCE subcomplex. We identified several important amino acids in this N-
terminal region but, surprisingly, many amino acid changes failed to affect the
function of the FANCF protein. Our data demonstrate that FANCF acts as a flexible
adaptor protein that plays a key role in the proper assembly of the FA core complex.
France Léveillé, Eric Blom, Annette L. Medhurst, Patrick Bier,
El Houari Laghmani, Mark Johnson, Martin A. Rooimans,
Alexandra Sobeck, Quinten Waisfisz, Fré Arwert, K. J. Patel,
Maureen E. Hoatlin, Hans Joenje & Johan P. de Winter
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Introduction
Fanconi anemia (FA) is an autosomal recessive chromosomal instability syndrome.
The clinical phenotype of FA patients is characterized by congenital abnormalities,
progressive bone marrow failure, and a predisposition to cancer; particularly acute
myeloid leukemia and squamous cell carcinoma [1, 2]. The spontaneous
cytogenetic aberrations specific for FA cells are exacerbated upon treatment with
DNA cross-linking agents, such as mitomycin C (MMC) and diepoxybutane, which
suggests a DNA maintenance defect particularly in the handling of cross-link
damage.
     To date, somatic cell fusion studies have demonstrated 11 FA complementation
groups (A–C, D1, D2, E–G, I, J, L) [3] and eight of the FA associated genes have been
identified: FANCA, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG and
FANCL [4–12]. These FA genes encode ‘orphan proteins’ and no functional domains
have been found in their primary amino acid sequences, except for a RING finger in
FANCL [10] and multiple TPR motifs in FANCG [13]. In FANCF a region with
homology to RNA-binding protein ROM has been suggested to provide a clue for its
function [5].
     FANCA, FANCC, FANCE, FANCF, FANCG and FANCL assemble in a nuclear core
complex [10, 14–17], in which FANCG binds directly to FANCA and FANCF and
FANCC binds directly to FANCE [15, 16]. The nuclear core complex is essential for
the monoubiquitination of FANCD2 [18] and this modified form of FANCD2
colocalizes with BRCA1, RAD51 [19] and PCNA [20] in foci that also contain other
DNA repair proteins. Nevertheless, it is still unknown how monoubiquitinated
FANCD2 is involved in DNA repair and MMC resistance. Recently, biallelic mutations
in BRCA2 have been found in cell lines derived from FA-D1 patients, adding BRCA2
to the list of FA proteins [8]. The BRCA proteins are known to be involved in a
multitude of biological functions including DNA repair, recombination, cell cycle
control and transcription [21]. BRCA2 appears to be directly linked to the repair of
double-stranded breaks (DSBs) by homologous recombination [22]. FANCD2 has
also been identified as a target of the ataxia telangiectasia (AT) signaling pathway
[23] and seems to be functionally connected to the RAD50/MRE11/NBS1 (RMN)
protein complex [24, 25], which plays an important role in the repair of DSBs [26].
Taken together, these data suggest that the FA proteins serve to maintain genomic
stability and integrity, in concert with other protein complexes.
     FANCF plays an important role in the FA pathway and its functional disruption
seems to be involved in specific types of cancer, as suggested from the
hypermethylation of the FANCF promoter in a subset of ovarian, oral, lung and
cervical cancers [27–29]. Nevertheless, the function of FANCF is still poorly
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understood. Patient-derived mutant forms of FA proteins and structure/function
analysis of FANCA, FANCC and FANCG have been informative in finding important
functional residues [30–34], but for FANCF this information is lacking, since none of
the FA-F patients have missense mutations that could provide insight into its
function [5]. For this reason, we started a site-directed mutagenesis study to obtain
more information about functional domains in the FANCF protein. Because such
domains are expected to be relatively conserved during evolution, we searched for
FANCF homologs in lower vertebrates that might highlight important residues in
FANCF. We found a Xenopus laevis homolog of FANCF (xFANCF), which has a
relatively low overall homology with human FANCF. However, two relatively
conserved regions were located at the N- and C- terminus. Based upon this
conservation we generated a large panel of FANCF mutants and identified several
functionally important amino acids and domains in FANCF. This study reveals that
FANCF is an adaptor protein that plays a key role in the proper assembly of the FA
core complex. To be able to perform this function the N-terminus of FANCF
interacts with the FANCC/FANCE subcomplex, while the C-terminus binds to the
FANCA/FANCG subcomplex.
Material and methods
Cell culture and transfection – Epstein-Barr virus (EBV)-transformed lymphoblasts
were cultured in RPMI 1640 media supplemented with 1 mM glutamine (Gibco,
Invitrogen, Carlsbad, CA, USA) and 10% fetal calf serum (FCS; Gibco). Selection
medium to obtain stable cell lines also contained hygromycin B (100 µg/ml; Roche,
Basel, Switzerland). For stable expression lymphoblastoid cell lines were transfected
by electroporation using an ECM830 electro square porator (BTX, San Diego, CA,
USA). The MMC-induced growth inhibition assays were performed as previously
described [35, 36].
Generation of FANCF mutant constructs – The FANCF mutant constructs were
generated by polymerase chain reaction (PCR) with oligonucleotides encoding the
amino acid substitutions or deleted regions of the FANCF sequence. We used as a
template the FANCF cDNA clone 10 obtained by expression cloning [5]. The FANCF
mutant R47A+F48A was made using the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s instructions. All
FANCF mutants have been analyzed by sequencing to confirm that the desired
changes had occurred and to exclude the presence of other PCR derived alterations.
The mutants were subcloned into the expression vector pCEP4 (Invitrogen) and
transfected in FA-F lymphoblasts, EUFA698. FANCF mutants 1-15del and delC31,
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and wild type FANCF-Flag were also subcloned into the expression vector pIRESneo
(Clontech, Palo Alto, CA, USA) to generate stable cell lines. Expression of the mutant
proteins in the stable cell lines was confirmed by immunoprecipitation and
immunoblotting with FANCF specific antibodies.
Sequence analysis – FANCF mutants and the Xenopus laevis FANCF IMAGE clone
3200942 (obtained from HGMP Resource Centre, Cambridge, UK), were subcloned
in pBluescript SK– and were sequenced with CY5.5 labeled T7 and T3 primers using a
Thermo Sequenase primer cycle sequencing kit (Amersham). Products were
analyzed on a Visible Genetics automatic DNA sequencer (Visible Genetics Inc,
Toronto, Ontario, Canada).
Yeast two-hybrid analysis – The MATCHMAKER Two-Hybrid System 3 (Clontech) was
used according to the manufacturer’s instructions as previously described [15]. In
brief, bait and prey constructs were sequentially transformed into AH109 yeast cells
and selected on -trp-leu-his-ade medium. The resulting colonies were tested for β-
galactosidase expression with X-gal. To confirm interactions a yeast-mating assay
was used where constructs were transformed separately into two different yeast
strains and mating cultures plated onto selection medium as above. All constructs
were tested for self-activation against a series of control plasmids and expression of
the mutant proteins was verified by immunoblotting.
Mammalian two- and three-hybrid analysis – Human embryonic kidney cells 293,
either untransfected or stably transfected with wild type or mutant (L554P) FANCC
were plated onto six well plates. After 48h, the cells were transiently transfected
with FANCE cDNA fused to the GAL-4 activation domain (pVP16; Clontech) and the
indicated FANCF constructs fused in frame to the GAL4 DNA-binding domain (pM;
Clontech) (1 µg of each), together with a GAL4 driven reporter plasmid (G5E1bLUC,
0.2 µg). The luciferase activity was monitored after 24 h using a Dual-Luciferase
Reporter Assay System (Promega) and a single tube luminometer (DLReady,
Berthold Detection Systems), according to the manufacturer’s instructions. All GAL4
constructs were sequenced to confirm the correct reading frame and each
experimental data set was performed in triplicate to overcome the variability
inherent to transfections. Transient expression of the FANCF constructs and stable
expression of FANCC were confirmed by immunoblotting with FANCF and FANCC
specific antisera.
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Subcellular fractionation, immunoprecipitation and immunoblotting – Nuclear and
cytoplasmic fractions of the lymphoblastoid cell lines were obtained as described
previously [17]. Cell extracts (~107 cells) were prepared in lysis buffer (50 mM Tris pH
7.4, 150 mM NaCl and 1% Nonidet NP40 supplemented with protease inhibitors)
and subjected to immunoprecipitation using the indicated antibodies, as previously
described (14). Anti-Flag M2 affinity gel (Sigma-Aldrich, Saint-Louis, MO, USA) was
used to immunoprecipitate Flag-tagged proteins. Immunoprecipitates or lysates
were then separated on 8% SDS-polyacrylamide gels, transferred to PVDF
membranes and specific proteins were detected by immunoblotting with the
indicated antibodies.
Results
Homology between the human and Xenopus FANCF proteins – Since functionally
important amino acids are well conserved between species, we searched several
databases for FANCF homologs to obtain clues about functional domains. In the
NCBI database an IMAGE clone (3200942) was found, which represented the full-
length Xenopus laevis homolog of FANCF (xFANCF). The cDNA was sequenced and
the predicted protein was aligned with the human FANCF sequence (Fig. 1). The
overall homology between both sequences appeared to be limited (27% identity,
49% similarity) and dispersed over the whole molecule. However, relatively high
sequence conservation was found in both the N- and C-terminal regions of the
protein. To test if this limited homology was sufficient to function in a human
background, Flag-tagged xFANCF was transfected into a cell line from an FA-F
patient (EUFA698). Unlike the human protein, xFANCF was unable to complement
the MMC hypersensitivity of the cells, despite of its proper expression (Fig. 2). The
untagged xFANCF protein was also unable to complement the MMC defect in FA-F
cells (data not shown), indicating that xFANCF is not able to restore the human FA
pathway.
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Fig. 1. Sequence alignment of human and Xenopus laevis FANCF proteins. Alignments were made with
BoxShade. The black-shaded residues are identical and the gray-shaded residues are similar between human
and Xenopus FANCF. The box shows the region homologous to the prokaryotic RNA-binding protein ROM.
The asterisks point out the amino acids essential for RNA-binding activity in ROM and the triangles indicate
the amino acids that were mutated in the ROM homologous region. The N- and C-terminal deletion mutants
that were generated are also indicated. GenBank Accession Number for xFANCF: AY547288.
Fig. 2. Xenopus FANCF protein is not functional in human cells. (A) The MMC hypersensitive phenotype of the
FA-F lymphoblastoid cell line EUFA698 is corrected by stable transfection with cDNA encoding human
FANCF, but not with cDNA encoding Xenopus FANCF. (B) Expression of Flag-tagged human and Xenopus
FANCF proteins in EUFA698 cells. Cell lysates of the indicated cell lines were immunoprecipitated with anti-
flag antibody and immunoblotted with rabbit FANCA antiserum 89 and anti-flag.
F1-15del
hFANCF   1 MESLLQHLDRFSELLAVSSTTYVSTWDPATVRRALQWARYLRHIHRRFGRHGPIRTALER
xFANCF   1 MHTMLENLDRFIELLTLSQSVHVKDWDILCVRRGFEWGSYFQQVYHRFCANDCLRNALED
hFANCF  61 RLHNQWRQEGGFGRGPVPGLANFQALGHCDVLLSLRLLENRALGDAARYHLVQQLFPGPG
xFANCF  61 HLRSKNQKLSTCIKN--YQYISFNDLRHSKDIFCTSLLQNKALSRNIFQYIVTKLK----
hFANCF 121 VRDADEETLQESLARLARRRSAVHMLRFNGYRENPNLQEDSLMKTQAELLLERLQ-EVGK
xFANCF 115 -NQSSGETNTCNMSNIMCQKAASALLLFPSSIDSKNPLENPCAVTEAEILKNHLEYRIHS
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The FANCF region homologous to ROM is not conserved and not essential for function –
FANCF was first described as a novel protein with homology to the prokaryotic
RNA-binding protein ROM [5]. The sequence alignment shows that the FANCF
region homologous to ROM (amino acids 145-209) is not well conserved between
human and Xenopus FANCF. Furthermore, the amino acids essential for RNA
binding (Gln-166 and Arg-173) are not identical in xFANCF. To further study this
region, Arg-173 was changed into alanine and the mutant protein was tested for its
ability to complement the MMC hypersensitivity of FA-F cells. Although this amino
acid change abolished RNA binding in ROM [37], it did not have an effect on the
activity of FANCF (Fig. 3). Similarly, FANCF mutants of the glutamic acid that is
identical between hFANCF and ROM (E172A and E172P) were still functional. These
data suggest that the FANCF region homologous to ROM is unlikely to have an
essential ROM-like function.
The C-terminus of FANCF binds directly to FANCG – Relatively high sequence
conservation was found in the C-terminus of FANCF (Fig. 1). To study the function of
this conserved region, several deletion constructs were generated and tested for
their ability to complement the MMC hypersensitive phenotype of FA-F cells.
Surprisingly, FANCF mutants with C-terminal deletions of 23, 31 or 40 amino acids
all complemented the MMC hypersensitivity of FA-F cells (Fig. 4A), although the
survival curves were slightly shifted towards a higher sensitivity when more amino
acids were deleted. Consistent with the notion that FANCD2 monoubiquitination is
required for MMC resistance, FA-F cells transfected with the delC31 mutant
expressed monoubiquitinated FANCD2 under normal conditions and after MMC
treatment (data not shown). Co-immunoprecipitation experiments showed that the
FANCF deletion mutants had a reduced interaction with FANCA and FANCG when
compared to wild type FANCF (Fig. 4B). Deletion of 31 or 40 amino acids completely
abolished the interaction in this assay. Since FANCF has been shown to interact
directly with FANCG [15, 38], we tested the interaction between FANCG and the
deletion mutants in a yeast two-hybrid assay. In both co-transformation and mating
experiments the mutants with a deletion of 31 or 40 amino acids had a strongly
reduced FANCG binding (Table 1). These results demonstrate that the last 31-40
amino acids in the C-terminus of FANCF are important for the direct interaction with
FANCG. By interfering with the binding to FANCG, the interaction with FANCA is
also disturbed, indicating that the C-terminus of FANCF is binding the
FANCA/FANCG subcomplex through FANCG.
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Fig. 3. The FANCF region homologous to ROM is not required to correct the MMC hypersensitivity of FA-F
cells. Sequence alignment showing the homology between human FANCF and the prokaryotic RNA-binding
protein ROM. The asterisks point out the amino acids essential for RNA-binding activity in ROM and the
triangles indicate the amino acids that were mutated. The MMC hypersensitive phenotype of the FA-F
lymphoblastoid cell line EUFA698 is corrected to wild type levels by stable transfection with cDNAs encoding
the FANCF mutants R173A, E172A and E172P. Lymphoblastoid cell line HSC93 is shown as a wild-type
control.
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Fig. 4. Deletion mutants of the C-terminus of FANCF are functional, but do not stably interact with FANCA
and FANCG. (A) The MMC hypersensitive phenotype of the FA-F cell line EUFA698 is corrected after stable
transfection with FANCF mutants that lack 23 (FdelC23), 31 (FdelC31) or 40 (FdelC40) amino acids of the C-
terminus. Lymphoblastoid cell line HSC93 is shown as a wild-type control. (B) Cell lysates from wild-type
(HSC93), FA-F (EUFA698) and the indicated stably transfected FA-F lymphoblasts were immunoprecipitated
with guinea pig anti-FANCF1-245 and immunoblotted with rabbit FANCA antiserum 89, rabbit anti-FANCG83-622
and rabbit anti-FANCF1-374 to show precipitated FANCA, FANCG and FANCF. The asterisks indicate the position
of FANCG.
The N-terminus of FANCF is involved in binding of the FANCC/FANCE subcomplex- We
next evaluated the function of a deletion mutant that lacked the highly conserved
first 15 amino acids of FANCF. The mutant FANCF protein was not able to
complement the MMC hypersensitivity of FA-F cells, despite its proper expression
and nuclear localization (Fig. 5). Although this mutant protein interacted with
FANCA and FANCG, the interaction was weak compared to that of wild type FANCF
(Fig. 4B and Fig. 8B).
Fig. 5. Deletion of amino acids 1 to 15 inactivates FANCF, without affecting the nuclear localization. (A) The
MMC hypersensitive phenotype of the FA-F cell line EUFA698 is not corrected after stable transfection of
cDNA encoding a FANCF mutant from which the first N-terminal 15 amino acids were deleted (F1-15del).
Lymphoblastoid cell line HSC93 is shown as a wild-type control. (B) Subcellular localization of FANCF mutant
F1-15del. Equal amounts of cytoplasmic (C) and nuclear (N) proteins from wild-type (HSC93), FA-F (EUFA698)
lymphoblasts and EUFA698 stably transfected with FANCF mutant F1-15del (EUFA698 + F1-15del) were
immunoprecipitated with anti-FANCF1-245. Precipitated FANCF was visualized by immunoblotting with rabbit
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Unlike wild-type FANCF, which can be immunoprecipitated in a complex with
FANCE, we did not detect any FANCE in a complex with the N-terminal deletion
mutant of FANCF using antisera against FANCE (Fig. 6A). Furthermore, the mutant
protein did not restore the interaction among FANCE, FANCA and FANCG that is
observed in wild-type cells. Similarly, the C-terminal deletion mutant lacking the last
31 amino acids was unable to bind FANCE and could not form a stable FA complex
(Fig. 6A). In a reciprocal experiment, FANCC and FANCE did not co-
immunoprecipitate with the N-terminal deletion mutant (Fig. 6B). Taken together,
these results indicate that the N-terminus of FANCF is essential for its function and
is involved in the binding of FANCC and FANCE.
     An important question for functional studies is how these proteins associate in
the core complex. Previously, no direct interaction between FANCF and FANCC or
FANCE has been found in yeast two-hybrid assays [15, 38], suggesting that the
association with FANCC and FANCE is indirect. We investigated these interactions in
a mammalian two-hybrid assay and also in this assay FANCF did not interact with
FANCC or FANCE (Fig. 6C), while an interaction between FANCC and FANCE was
observed. We then sought to determine if the N-terminus of FANCF might be
involved in the binding of this FANCC/FANCE subcomplex, using a mammalian
three-hybrid (M3H) system, with 293 cells stably overexpressing FANCC. In this
assay, we observed a strong induction of the reporter gene when FANCF was
cotransfected with FANCE (Fig. 6D), indicating that FANCC acts as a molecular
bridge between FANCF and FANCE. As a control experiment, we used a 293 cell line
stably overexpressing FANCC mutant L554P, which is defective in binding FANCE
[16, 38] and found no interaction between FANCF and FANCE (data not shown). To
further extend these observations, we tested the FANCF N- and C-terminal deletion
mutants in the M3H assay. In agreement with our co-immunoprecipitation
experiments, the FANCF mutant 1-15del completely failed to interact with FANCE,
whereas the FANCF mutant delC31 had a reduced interaction (Fig. 6D). Collectively,
these observations indicate that the first 15 amino acids of FANCF are essential for
the direct binding of the FANCC/FANCE subcomplex. Furthermore, they
demonstrate that this interaction also partially depends on the C-terminal part of
the FANCF protein.
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The N-terminus of FANCF contains several residues essential for its function – Several
missense mutants were generated to delineate amino acids in the N-terminal
region of FANCF essential for its interaction with the other FA proteins and for its
ability to complement the MMC defect in FA-F cells (see Table II). Secondary
structure prediction programs indicate that the first 15 amino acids of human
FANCF form an amphipathic α-helix (Fig. 7), with a strong negative charge at one
side of the helix (Glu-2, Asp-9 and Glu-13). In the Xenopus homolog a similar
structure was predicted, with Glu-6, Asp-9 and Glu-13 at the negative side of the
helix.
     These negatively charged amino acids were either changed into alanines
(E2A+D9A+E13A) or replaced by positively charged lysines (E2K+D9K+E13K) and
the mutants were tested for their ability to complement the MMC hypersensitivity
of FA-F cells, and for their ability to interact with FANCA. Both mutants were able to
complement the MMC defect (Fig. 8A), but like the N-terminal deletion mutant, the
E2K+D9K+E13K mutant appeared to have a reduced interaction with FANCA (Fig.
8B). Since the C-terminus of FANCF is also involved in the interaction with FANCA
(Fig. 4B), we tested mutants with a combination of mutation and deletions to
determine if the N- and C-terminal conserved regions of FANCF act in concert.
When the last 23 C-terminal amino acids were removed, the E2A+D9A+E13A
mutant was still biologically active, whereas the E2K+D9K+E13K mutant became
inactive (Fig. 8C). We then removed 31 C-terminal amino acids of these mutants and
found that this completely abolished the activity of both mutants (Fig. 8D). Thus,
reversing the charges of the residues in the FANCF α-helix is more disruptive than
neutralizing the negatively charged residues. We infer that the three negatively
charged amino acids in the first N-terminal α-helix of FANCF are functionally
important and that FANCF has partially interdependent functional terminal
domains.
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Fig. 6. Interaction of FANCF mutants with the FANCC/FANCE subcomplex. (A) Cell lysates from wild-type
(HSC93), FA-F (EUFA698) lymphoblasts and FA-F cells stably transfected with the indicated FANCF mutants
were immunoprecipitated with anti-FANCE and immunoblotted with anti-FANCA serum 89, anti-FANCG83-622,
anti-FANCF1-374 and anti-FANCE to visualize FANCA, FANCG, FANCF and FANCE respectively. The asterisks
indicate the position of FANCG. (B) EUFA698 cells were stably transfected with cDNAs encoding the FANCF
mutant F1-15del-flag and wild-type FANCF-flag in expression vector pIRESneo. Immunoprecipitation was
performed with anti-flag resin and immunoprecipitated FA proteins were visualized by immunoblotting with
anti-FANCA serum 89, anti-FANCC106-558, anti-FANCE and anti-FANCF1-374. (C) Mammalian two-hybrid assay
indicating a lack of direct interaction between FANCF and FANCC or FANCE. Fold induction is expressed
relative to the luciferase activity obtained with empty vectors (pM and pVP16). (D) Mammalian three-hybrid
assay illustrating the interaction of FANCF and FANCF mutants with the FANCC/FANCE subcomplex. Fold
induction is expressed relative to the luciferase activity obtained with the pVP16-AD-FANCE vector alone.
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Fig. 7. The N-terminus of FANCF contains two amphipathic α-helices. Sequence alignment showing the
homology between the N-terminus of human and Xenopus laevis FANCF. Two amphipathic α-helices were
predicted by Jpred and DNAsis software. The arrows indicate the hydrophobic moment of the helices. The
functionally important amino acids are in bold and underlined. Asterisks (*) indicate the serine-threonine
stretch.
The hydrophobic side of the N-terminal α-helix contains three conserved leucines
(Leu-5, Leu-8 and Leu-15). When these leucines were replaced by alanines, the
mutant protein was functional in an MMC test (Fig. 9A). However, this mutant was
totally inactivated upon removal of the 31 C-terminal amino acids (Fig. 9A), hinting
that the conservation at the hydrophobic side of the helix is of functional
significance. We then examined the ability of the FANCF mutant L5A+L8A+L15A
(with an intact C-terminus) to interact with the FANCC/FANCE subcomplex in the
M3H assay and found that this mutant failed to activate transcription of the
luciferase reporter gene (Fig. 9C). These results suggest that the three leucines
residues are involved in the direct binding of the FANCC/FANCE subcomplex.
     We further investigated N-terminal mutants, in which combinations of the
conserved arginine (Arg-10) or phenylalanine (Phe-11) residues were modified. All
the single mutants were able to complement the MMC hypersensitivity of FA-F cells
(Table II) and displayed a normal interaction with FANCA (Fig. 8B). These mutants
were still functional when the C-terminal 31 amino acids were removed (Table II).
However, a double mutant in which both Arg-10 and Phe-11 were changed into
alanine (R10A+F11A) had a reduced biological activity, but only in combination
with a C-terminal deletion of 31 amino acids (Fig. 9B). A possible explanation for the
partial inactivation of the protein is the prediction of a similar α-helix (amino acids
hFANCF1-60     MESLLQHLDRFSELLAVSSTTYVSTWDPATVRRALQWARYLRHIHRRFGRHGPIRTALER
xFANCF1-60     MHTMLENLDRFIELLTLSQSVHVKDWDILCVRRGFEWGSYFQQVYHRFCANDCLRNALED
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31-48), in which a conserved arginine (Arg-47) and phenylalanine (Phe-48) are
found (Fig. 7). These amino acids might be able to partially compensate for the
amino acid changes in the first α-helix. To test this hypothesis, we constructed a
mutant in which the arginines and phenylalanines in both helices were replaced by
alanines (R10A+F11A+R47A+F48A). When combined with a deletion of the C-
terminus, this mutant was totally inactive (Fig. 9B). A mutant in which only Arg-47
and Phe-48 were changed (R47A+F48A) was functional (Fig. 9B). These results
indicate that the conserved arginines (Arg-10 and Arg-47) and phenylalanines (Phe-
11 and Phe-48) in the first and second α-helix may form a functional unit. The M3H
assay was used to show that the R10A+F11A+R47A+F48A mutant (with an intact C-
terminus) was unable to interact with the FANCC/FANCE subcomplex (Fig. 9C),
suggesting that these arginine and phenylalanine residues participate in this direct
interaction.
Fig. 8. The negatively charged amino acids in the first N-terminal α-helix of FANCF have an important
function. (A) The MMC hypersensitive phenotype of the FA-F cell line EUFA698 is corrected after stable
transfection of cDNAs encoding FANCF mutants in which the negatively charged amino acids Glu-2, Asp-9
and Glu-13 were mutated. Lymphoblastoid cell line HSC93 is shown as a wild-type control. (B) Cell lysates
from FA-F lymphoblasts (EUFA698) and FA-F lymphoblasts stably transfected with the indicated FANCF
mutants were immunoprecipitated with guinea pig anti-FANCF1-245 and immunoblotted with rabbit FANCA
antiserum 89 and rabbit anti-FANCF1-374 to show the interaction between the different FANCF mutants and
FANCA. (C) Deletion of 23 amino acids from the FANCF mutants in which the negatively charged amino acids
were mutated does only affect the ability of the E2K+D9K+E13K mutant to complement the MMC
hypersensitive phenotype of the FA-F cell line EUFA698. (D) The FANCF mutants in which the negatively
charged amino acids were mutated are unable to complement the MMC hypersensitive phenotype of the FA-
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Fig. 9. Other functional important amino acids in the N-terminus of FANCF. (A) A FANCF mutant in which
Leu-5, Leu-8 and Leu-15 are changed into alanines is not able to complement the MMC hypersensitive
phenotype of EUFA698 cells after removal of the C-terminal 31 amino acids. (B) Effect of arginine and
phenylalanine-substitutions in FANCF on the ability to complement the MMC hypersensitive phenotype of
EUFA698 cells. FANCF mutants R10A+F11A and R10A+F11A+R47A+R48A are inactivated upon removal of
the C-terminus. (C) Mammalian three-hybrid assay illustrating the disturbed interaction between the FANCF
mutants 3xL (L5A+L8A+L15A) and 2xRF (R10A+F11A+R47A+R48A) and the FANCC/FANCE subcomplex.
Results shown are mean ± standard deviation (SD) and derived from an experiment in triplicate. Fold
induction is expressed relative to the luciferase activity obtained with the pVP16-AD-FANCE vector alone. (D)
A FANCF mutant in which Ser-18, Ser19, Thr-20 and Thr-21 are changed into alanine is not able to
complement the MMC hypersensitive phenotype of EUFA698 cells after removal of the C-terminal 31 amino
acids. (E) Mammalian three-hybrid assay showing interaction of the FANCC/FANCE subcomplex with wild
type FANCF and FANCF mutant S18A, which is lost in the FANCF mutant S18A-S19A-T20A-T21A (SSTT/A).
In order to investigate whether the two predicted N-terminal α-helices are really
being formed and function as a unit, several leucine to proline mutants were made
to disrupt the helical structure of this region (Table II). The disruption of the first α-
helix by substitution of Leu-8 or Leu-14 as well as the disruption of the second α-
helix by substitution of Leu-41 interfered with the biological activity of the protein,
but again only when the C-terminal 31 amino acids were removed. As a control, we
replaced Leu-14 by alanine and deleted its C-terminus, and found that this did not
affect the function of the protein. These results imply that the two N-terminal α-
helices in FANCF form a functionally important structure, which cooperates with the
C-terminus of the protein.
     A serine and threonine stretch (Ser-18, Ser-19, Thr-20, Thr-21) is located just after
the first N-terminal α-helix. To investigate the functional significance of this region
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removal of its C-terminus (Fig. 9D). However, a mutant (S18A) in which only the
conserved Ser-18 was changed to an alanine appeared to be functional (Fig. 9D).
Subsequent analysis of these FANCF mutants (with an intact C-terminus) in the M3H
assay showed that only the mutant S18A was able to activate the luciferase reporter
gene (Fig. 9E). These data suggest that the serine and threonine stretch is of
functional importance and is involved in the binding of the FANCC/FANCE
subcomplex.
Amino acids 76 to 84 are not essential for the function of FANCF – FA-F patient
EUFA698 has a 23 bp deletion in the FANCF gene resulting in a frame shift at codon
77 (5). Since the deleted region is poorly conserved between human and Xenopus
FANCF, we tried to overcome the defect by selection for a phenotypic revertant in
vitro. After long-term culture of a lymphoblastoid cell line from patient EUFA698 in
the presence of 15 nM MMC a MMC resistant cell line was obtained. Sequence
analysis indicated that a deletion of nucleotide 225 (225delT) had restored the
FANCF reading frame in one allele of the reverted cell line (Fig. 10). In the mutant
protein, Pro-76 is changed into a glutamine while amino acids 77 to 84 are absent.
This FANCF mutant is expressed and has a normal interaction with FANCA (Fig. 10).
These data therefore indicate that amino acids 76 to 84 are not essential for the
complementing activity of the FANCF protein and support the idea that the
structure of FANCF is rather flexible.
Fig. 10. Amino acids 76 to 84 are not essential for the function of FANCF. A 23 base pair deletion (230-252del)
in FA-F patient EUFA698 results in a frame shift at codon 77 (Val-77). The FANCF reading frame is restored by
a deletion of nucleotide 225 in revertant cell line EUFA698R, which changes Pro-76 into Gln and deletes
amino acids 77 to 84. Cell lysates from wild type lymphoblasts (HSC93), FA-F lymphoblasts (EUFA698) and the
reverted FA-F lymphoblasts (EUFA698R) were immunoprecipitated with guinea pig anti-FANCF1-245 and
















WT   GGG CGG GGT CCA Gtt ccg gga tta gcg aac ttc cag GCC CTC GGT
      G   R   G   P   V   P   G   L   A   N   F   Q   A   L   G
                     ↓230-252del
698  GGG CGG GGt CCA GGC --- --- --- --- --- --- --- --CCT CGG T
      G   R   G   P   G                                 P    R
                     ↓225delT
698R GGG CGG GGC CAG --- --- --- --- --- --- --- --- GCC CTC GGT
      G   R   G   Q                                   A   L   G
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Table 2. Activity of the FANCF mutants in different assays









delC31 + - na ↓
1-15del - ↓ nd -
Q6A + + + nd
D9A + R10A + nd + nd
R10A + + + nd
R10E + + + nd
F11A + + + nd
F11Y + + + nd
R10A + F11A + + ↓ -
F11A + E13A + + ↓ nd
R47A + F48A + + + nd
R10A + F11A + R47A + F48A + nd - -
E2A + D9A + E13A + + - nd
E2K + D9K + E13K + ↓ - nd
L5A + L8A + L15A + ↓ - -
L8P + nd - nd
L14P + nd - nd
L14A + + + nd
L41P + + - nd
L8P + L41P + nd nd nd
L14P + L41P + nd nd nd
S18A + + + +
S18A + S19A + T20A + T21A + + - -
+ = normal activity; ↓ = reduced activity; - = no activity; na= not applicable; nd = not determined
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Discussion
Highly conserved amino acids are generally thought to be critical for a protein’s
function. By using an extensive site-directed mutagenesis approach we have
investigated the functional importance of amino acids that are conserved between
human and Xenopus laevis FANCF. Our results demonstrate that the C-terminus of
FANCF binds directly to FANCG and is required for stable interaction with FANCA,
FANCC and FANCE. Furthermore, we found that the N-terminus of FANCF is
essential for the direct interaction with the FANCC/FANCE subcomplex, and is
important for stabilizing the complex formation with FANCA and FANCG. This study
shows that FANCF is an adaptor protein, which keeps the other components of the
FA core complex together in such a way that they can perform their function.
     A direct interaction between FANCF and FANCG has been demonstrated using
the yeast two-hybrid system [15] and the carboxy terminus of FANCF (amino acids
243-374) was shown to be essential for this interaction [38]. In the current study, we
found that the interaction site is specifically located in the strongly conserved last
31 amino acids (amino acids 343-374) of FANCF and that this particular region
provides stability to the FA core complex. Surprisingly, the C-terminal deletion
mutants were still able to complement the MMC hypersensitivity of FA-F cells and
to support the monoubiquitination of FANCD2. The ability of the FANCFdelC31
mutant to complement FA-F cells was not a result of overexpression of this protein,
since low expression levels of this mutant protein by a leaky inducible vector
(pMEP4) or by stable integration (pIRESneo) still corrected the MMC hypersensitivity
[J.P. de Winter et al., unpublished data]. Since the mutant FANCFdelC31 also
corrects the MMC hypersensitivity of FA-F patient cell line EUFA1228 [J.P. de Winter
et al., unpublished data], the complementing activity of this mutant is also not cell
line dependent. We infer from our results that the FANCFdelC31 mutant protein has
a reduced affinity for the other members of the complex, undetectable in co-
immunoprecipitation experiments because of the stringent conditions of this assay,
but sufficient for a functional FA pathway. This conclusion is supported by our data
showing an interaction between the FANCFdelC31 mutant and the FANCC/FANCE
subcomplex in the mammalian three hybrid assay, which was undetectable in co-
immunoprecipitation experiments.
     The first 15 amino acids of FANCF are predicted to form an α-helix sharing 60%
homology with Xenopus FANCF. This region is essential for the function of FANCF,
since a FANCF mutant in which these amino acids were deleted failed to correct the
MMC hypersensitivity of EUFA698 cells. This FANCF mutant appeared to have a
normal nuclear localization and a reduced interaction with FANCA and FANCG,
indicating that this particular region in FANCF is not directly involved in the nuclear
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targeting of FANCF, but crucial for the stable binding to FANCA and FANCG.
Interestingly, the FANCF mutant 1-15del failed to co-precipitate with FANCC and
FANCE, suggesting that this particular N-terminal region in FANCF is required for
the presence of FANCC and FANCE within the FA core complex. The mammalian
three-hybrid system confirms this finding and provides strong evidence for direct
interaction between the first 15 amino acids of FANCF and the FANCC/FANCE
subcomplex.
     To identify functionally relevant residues in the N-terminus of FANCF, we
generated several mutations in the first 48 amino acids that contain two predicted
α-helices. Surprisingly, we could not obtain inactive or partially functional mutants
without the additional removal of the last 31 amino acids when we assayed for the
ability to complement the MMC hypersensitive phenotype of FA-F cells. This implies
that the FANCA-FANCG interaction needs to be disturbed before amino acid
substitutions in the N-terminus of FANCF show an effect in this assay. However,
when tested in the M3H assay, mutations in the N-terminus of FANCF were
sufficient to interfere with the binding of the FANCC/FANCE subcomplex.
Apparently, the binding of FANCA and FANCG to the C-terminus of FANCF stabilizes
the interaction of factors that bind to the N-terminus of FANCF, in particular the
FANCC/FANCE subcomplex. By removing the C-terminus of the FANCF protein we
interfered with this stabilizing effect. In the mammalian three hybrid assay we do
not need to interfere with the binding of the FANCA/FANCG subcomplex, since in
this assay FANCA and FANCG are not present. What we have essentially tested in
the mammalian three hybrid assay and the MMC test with the C-terminally
truncated N-terminal mutants is the same; the interaction with the FANCC/FANCE
subcomplex in the absence of the FANCA/FANCG subcomplex. Accordingly, the
results of both assays are the same. The detection of a weak interaction between
FANCA and FANCE [Ref 16 and Fig. 6A] and between FANCA and FANCC [14] in co-
immunoprecipitation experiments on lysates of FA-F patients indicates that these
FA proteins have some affinity for each other, but that these interactions need to be
stabilized by the presence of FANCF. The results of our experiments suggest that
binding of the FANCC/FANCE subcomplex to the N-terminus of FANCF (in case of
the C-terminal deletion mutants) or binding of the FANCA/FANCG subcomplex to C-
terminus of FANCF (in case of the N-terminal missense mutants) is sufficient to
activate the FA pathway.
     From the non-functional mutants we identified four critical regions defined by a
group of residues essential for the proper function of FANCF. One region consists of
3 consecutive negatively charged residues (Glu-2, Asp-9, Glu-13) located at one side
of the first α-helix. It is tempting to speculate that this region interacts through salt
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bridges with the 3 positively charged residues (Arg-32, Arg-39, Arg-46) located at
one side of the second α-helix to form a functional domain. Another important
region involves 3 conserved hydrophobic amino acids on one side of the first α-
helix (Leu-5, Leu-8, Leu-15), which appear to form a binding site for the
FANCC/FANCE subcomplex. The conserved arginines (Arg-10 and Arg-47) and
phenylalanines (Phe-11 and Phe-48) in the first and second α-helix form the third
critical region in the N-terminus of FANCF. These 4 residues combined are also
involved in the association with the FANCC/FANCE subcomplex and may either be a
part of the interaction domain or stabilize this domain. A fourth critical region in the
FANCF protein is formed by a stretch of serine-threonine residues in the loop region
between the two α-helices. Although there is no evidence as yet for
posttranslational modification of FANCF, this specific region could be the target for
phosphorylation by a serine/threonine kinase. Alternatively, these serines and
threonines might be involved in protein-protein interaction through the formation
of hydrogen bonds. Our data show that this particular region plays a role in the
direct interaction with the FANCC/FANCE subcomplex. Finally, the FANCF region
homologous to the prokaryotic RNA binding protein ROM (amino acid residues 145-
209) does not seem to have an essential ROM-like function. The FANCF mutants
R172A, E172P and R173A (equivalent in ROM to amino acids Q24 and R25,
respectively) did not affect the function of FANCF.
     We realize that these mutagenesis studies need to be interpreted with caution,
because of the risk to affect the general structure of the protein. However, since
amino acid changes in the N-terminus and even deletions of the C-terminus of
FANCF were tolerated, the FANCF structure seems to be very stable and flexible.
Also the fact that a deletion of the C-terminus only inactivates a subset of the N-
terminal FANCF mutants indicates that it is very difficult to affect the structure of
the FANCF protein. Consistent with this idea is that none of the identified FA-F
patients have missense mutations in FANCF, but rather have nonsense mutations or
deletions [5]. Furthermore, an in vitro revertant of EUFA698 cells expresses a mutant
FANCF protein that lacks amino acids 76 to 84, which is still functional. The only
mutation that might have changed the structure of the FANCF protein is the N-
terminal deletion mutant, since this is the only single mutant that is unable to
restore the MMC hypersensitivity of FA-F cells.
     Our results suggest a sequential recruitment of the FA gene products in which
the FANCF protein has a key role by linking the different subcomplexes
(FANCA/FANCG and FANCC/FANCE) and possibly other components together.
Therefore, we propose that FANCF acts as an adaptor protein that plays a key role in
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the proper assembly of the FA core complex. We infer from our and published data
that FANCF stabilizes the interaction between the FANCC/FANCE subcomplex and
the FANCA/FANCG subcomplex and locks the whole FA core complex in a
conformation that is essential to perform its function.
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Bioinformatic analysis of the
Fanconi anemia gene products
Background – The bone marrow failure and DNA repair disorder Fanconi anemia
(FA) is genetically highly heterogeneous, as defects in each of at least 9 different
genes can precipitate this disease: FANCA, -B, -C, -D1, -D2, -E, -F, -G, and -L. Functional
characterization of the individual gene products has been problematic, because
most are known as ‘orphans’, so that little information can be deduced from direct
comparison with proteins in the databases. We previously used a bioinformatic
approach, based on comparisons with distant orthologs in the bony fishes Danio
rerio and Oryzias latipes, to show the existence of TPR motifs in the FANCG protein.
We now extend this analysis to include other FANC proteins and additional software
such as coiled-coil prediction and protein fold recognition. FANCD1/BRCA2 was
excluded, since this protein has been studied extensively by others.
Results – Distinct features were discovered in four FANC proteins, i.e. FANCL,
FANCD2, FANCA, and FANCC. Contrary to what has been reported previously,
FANCL contains a RING finger domain rather than a PHD-type zinc finger domain. In
addition, FANCD2 may have a coiled coil structure and both FANCA and FANCC are
likely composed of multiple HEAT repeat-like motifs.
Conclusions – The bioinformatic strategy as outlined in this paper was successful in
extracting information on the domain structure of four FANC proteins. The
information allows the postulation of new testable hypotheses on the function of
these proteins.
Eric Blom, Fré Arwert & Hans Joenje
Unpublished results
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Introduction
Fanconi anemia (FA), a chromosomal instability syndrome characterized by aplastic
anemia, developmental defects and cancer predisposition, is genetically a highly
heterogeneous disease. To date, 11 complementation groups have been
distinguished (FA-A, B, C, D1, D2, E, F, G, I, J, and L), for 9 of which the corresponding
genes have been identified (FANCA, -B, -C, -D1, -D2, -E, -F, -G, and -L) [1-10].
Biochemical studies have revealed that most of the FANC proteins assemble in a
multisubunit protein ‘core complex’ composed of FANCA, -B, -C, -E, -F, -G, and –L,
which is required for activation via monoubiquitylation of the downstream
functioning FANCD2 protein [11, 12]. Interestingly, the breast cancer susceptibility
gene products BRCA1 and BRCA2 are also involved in the FA pathway, as the
FANCD2 protein forms nuclear repair foci with BRCA1 upon its monoubiquitylation,
while BRCA2 turned out be the same gene as FANCD1 [11, 13]. Furthermore, at the
cellular level, FA cells are extremely sensitive to agents that induce DNA interstrand
cross-links, such as mitomycin C and diepoxybutane, suggesting a role for the FA
pathway in the handling of this type of DNA lesion.
     Despite a considerable progress in FA research, the exact function of the
individual FANC proteins is poorly understood. This is partially caused by the fact
that most FANC proteins are ‘orphans’ having no homology to each other nor to
any other protein, making a bioinformatic analysis difficult or even impossible. A
positive exception has been the FANCG protein, which has recently been
characterized as a member of the tetratricopeptide repeat (TPR) family predicting a
role in the assembly of the FA protein core complex [14]. Results depended on the
application of an in-depth bioinformatic approach, which is used in this report to
analyze the remaining FANC proteins. The FANCD1/BRCA2 protein was excluded
from this analysis, since its domain structure has already been studied in great
detail by others: this protein contains 8 copies of a 39 amino acid repeat, the BRC
repeat, which is critical for binding to the DNA recombinational repair protein
RAD51 [15, 16].
Methods
Bioinformatic analysis was performed as outlined in the results and discussion
section. Database searches as BLAST, PSI-BLAST and the rpsblast tool were run at
the website of the National Center for Biotechnology Information (NCBI,
http://www.ncbi.nlm.nih.gov/BLAST/). For the prediction of putative coiled coil
regions the COILS program at http://www.ch.embnet.org/software/COILS_
form.html was used and for the prediction of protein families the Pfam server at
http://pfam.wustl.edu/. For protein fold recognition using mGenThreader the server
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at http://bioinf.cs.ucl.ac.uk/psipred/psiform.html was used and for the discovery of
protein repeats the REP program at http://www.embl-heidelberg.de/~andrade/
papers/rep/search.html.
Results and Discussion
FANCL: a really interesting new gene (RING) – Recently the FANCL protein, also known
as FAAP43, PHF9 or Pog, has been identified as a key component in the FA core
complex carrying the catalytic activity required for the monoubiquitylation of
FANCD2 [9]. In that study, FANCL has been described to contain three potential
WD40 repeats and a C-terminal PHD-type zinc finger motif, the latter motif being
claimed to be responsible for the ubiquitin ligase activity of FANCL. However, PHD
finger proteins typically occur in proteins involved in chromatin regulation and no
ubiquitin ligase activity has yet been reported for this type of domain [17, 18]. Here,
we show that this domain in FANCL contains a slightly atypical RING finger domain.
     The PHD (plant homeodomain) type zinc finger and the RING (really interesting
new gene) finger are closely related structures that do not resemble classical zinc
fingers. Both domains use their Cys/His residues to bind two zinc atoms in a unique
“cross-brace” fashion: the first and third pair of metal binding residues bind the first
zinc, and the second and fourth pair bind the second zinc (Fig 1A). This zinc ligation
is required for proper folding and is essential for the biological activity of both
domains. Because of their close resemblance it is difficult to distinguish between
PHD and RING fingers and several sequence-based approaches for the classification
of complex zinc fingers are in use. The simplest method uses a pattern that relies
exclusively on the nature and spacing of the cysteine and histidine residues that
ligate to the zinc ions. With this method PHDs are defined by the formula C-x2-C-x(09-
21)-C-x(2-4)-C-x(4-5)-H-x2-C-x(12-46)-C-x2-C and RINGs by C-x2-C-x(09-39)-C-x(1-3)-H-x(2-3)-C-x2-C-x(04-
48)-C-x2-C where x can be any residue. Clearly, this crude method qualifies FANCL as a
PHD finger since metal ligand 4 is a cysteine and metal ligand 5 is a histidine (Fig
1B). A second approach, which relies on the evolutionary relationship within protein
families, has recently been suggested to be superior for the discrimination between
PHDs and RINGs [17]. This method of protein classification is also used by several
databases such as Pfam [19] and has been proven to be highly successful for the
prediction of protein functionality. In order to classify FANCL, we performed a PSI-
BLAST database search [20] and found that the C-terminal domain of FANCL had
weak but statistically significant homologies with several other proteins (Fig 1B).
Interestingly, all of these proteins are classified as RINGs by Pfam indicating that the
motif in FANCL should be designated as a RING rather than as a PHD finger.
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     An additional observation favoring the RING comes from the hydrophobic core of
the motif. Although both RING and PHD domains have conserved hydrophobic
residues at the same positions, PHDs have an additional hydrophobic tryptophan
residue two positions N-terminal of the 7th metal ligand (Fig. 1B). This tryptophan,
which is highly conserved throughout the PHD family, is an essential part of the
hydrophobic core of PHDs [21]. This important residue is missing in FANCL (Fig. 1B),
which indicates that FANCL is not a PHD protein. In RING structures reported, the
residue that occurs at this position is solvent-exposed and is not part of the
hydrophobic core of the motif [21, 22].
     Taken together, FANCL contains a RING finger domain with a slightly atypical
Cys/His pattern that is similar to that of PHDs. This odd Cys/His pattern may be the
reason why Meetei et al. [9] have previously classified FANCL as a PHD, but this
pattern is of only minor importance since RINGs are flexible with regard to the
ligating residue, e.g. His can replace Cys and even Asp can be used as a Zn2+ ligand
[21]. Overall, the RING domain of FANCL closely resembles that of the RING
consensus and has a hydrophobic core that is typical for that of RINGs.
(a)
1  2                3    4       5  6                     7  8
PHF9_HUMAN (FANCL)           CGICYAYQLDG--TIPDQV-CDNSQCGQP---FHQICLYEWLRGLLTSRQSFNIIFGECPYC
CG12812_AAF54486       CNICFAYRLDGG-EVPLVS-CDNAKCVLK---CHAVCLEEWFKTLMDGKTFLEVSFGQCPFC
AAO52554_Arabidopsis   CPICYSMFHNGT--IPKFQ-CKT--CKNK---FHAGCIYKWFQT--SHKSN-------CPLC
EAK91327_Candida       CAICYSILHQ-DSSLPSKT-CTT--CSNK---FHAACLYKWFKS--SGSST-------CPLC
CAA88657_Saccharomyces CAICYSILHAVDRKLPSKT-CPT--CKNK---FHGACLYKWFRS--SGNNT-------CPLC
AAU20830_Caenorhabditis CTICMMTVHQQTHQLPKIK-CKQ--CKNK---FHSNCLYKWFES--SNQST-------CPLC
BAD28090_Oryza         CAICLAEFVDG----DTVRVMPV--CGHG---FHARCIERWLAG---GRRS------SCPTC
Pfam consensus zf-C3HC4 CrICleelkepsndfplilpCg...HsGslkyfCrsClerWlsssgnttv.......kCplC
Pfam consensus PHD CsvCgkpdddaggdllq...CCDg Cdrw...fHlaClgppleeppegk.......WlCpeC
(b)
Fig 1. (A) Zinc ligation pattern as found in RING domains. (B) Comparison of the RING domains of human
FANCL and its Drosophila ortholog CG12812 with several other RING domain-containing proteins. The
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FANCD2: a possible coiled coil protein – In 2001 the gene responsible for the defect in
FA-D2 cells was identified encoding a gene product of 1451 residues [5]. Like other
FANC proteins it does not contain known protein domains, but similar as the FANCL
protein it is more conserved throughout evolution, having orthologs also in non-
vertebrate species such as Drosophila melanogaster, Caenorhabditis elegans and
Arabidopsis thaliana [5, 23]. In the analysis shown here, evidence is presented
indicating that FANCD2 might contain a coiled coil domain similar to that of myosin
heavy chain, mitotic checkpoint proteins, or structural maintenance of
chromosomes proteins.
     The analysis of FANCD2 was started with a PSI-BLAST search since it is more
sensitive than BLAST for revealing distant homologs [20]. After the 2nd or further
iterations only orthologs of FANCD2 were found, except one 1663 amino acid A.
thaliana protein which is named ‘meprin and TRAF homology domain-containing
protein’ (Acc. no's: NP_180104, AAD23659 or A84647). Since in this case these
ortholog sequences gave little information about the domain structure, the analysis
was further focused on the Arabidopsis protein. As shown in figure 2A two regions
in the N-terminus of FANCD2 are homologous to the central part of the Arabidopsis
protein, i.e. region 9-167 and 174-495 of FANCD2 with region 689-840 and 944-1310
of the Arabidopsis protein, respectively.
     Analysis of the Arabidopsis protein using the conserved domain database search
(rpsblast at the NCBI website) revealed that four N-terminal MATH domains are
present (Fig 2A). The MATH domain (meprin and TRAF homology) is a domain
present in both extracellular mammalian tissue-specific endopeptidases (meprins)
and in intracellular proteins interacting with TNF receptors (TRAF proteins). Since
the homology between FANCD2 and the Arabidopsis protein is not based on the
presence of a MATH domain in FANCD2 (Fig 2A), this domain is not further
discussed here. At the C-terminus, the rpsblast tool predicted either a MAD or Smc
domain but both were only partially present, with 26% aligned (E value 9×10-6) and
20% aligned (E value 3×10-11), respectively. The MAD domain (mitotic arrest-
deficient) is present in several mitotic checkpoint proteins such as yeast Mad1p that
monitor proper attachment of the bipolar spindle to the kinetochores of aligned
sister chromatids and causes a cell cycle arrest when failure occurs. In addition, the
Smc domain (structural maintenance of chromosomes) is present in chromosome
segregation ATPases. An interesting member of this family is the S. pompe Rad18
protein that acts in a DNA repair pathway for removal of UV-induced DNA damage
and ionizing radiation damage that is distinct from classical nucleotide excision
repair pathway and is probably also involved in the maintenance of chromatin
structure.
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     Like the MATH domain, the homology between FANCD2 and the Arabidopsis
protein does not seem to be based on the presence of a MAD/Smc-like domain in
FANCD2: only the central part between the four N-terminal MATH domains and the
C-terminal MAD/Smc-like domain of the Arabidopsis protein is homologous to
FANCD2. However, further analysis of the Arabidopsis protein using PSI-BLAST
revealed that the C-terminal MAD/Smc-like domain is extended towards the N-
terminus (Fig 2A). This region is highly repetitive and homologous to myosin heavy
chain-containing proteins. Although this region appears to start at residue 1068,
upon further iterations using the PSI-BLAST program it appears to be extended
even more towards the N-terminus, as indicated by the arrow in figure 2A. This
result shows that myosin heavy chain and MAD/Smc-like domains are related and,
more importantly, that FANCD2 may contain a similar domain at its N-terminus.
Coiled coil domains are protein-protein interaction motifs consisting of two or more
α-helices that twist around each other forming a supercoil. Coiled coil proteins can
be both heterodimers or homodimers and usually form ‘rod’-like structures
providing the cell with cables and networks in the cyto- and nucleocytoskeleton
and molecular scaffolds that organize membrane systems and molecular motors
[24]. To test for the possible presence of a coiled coil region in both the Arabidopsis
protein and in FANCD2, the COILS program [25] was used (Fig 2B). In the Arabidopsis
protein, a high probability of forming a coiled coil region was found in region 1300-
1600, which is in agreement with the predicted MAD/Smc-like domain. In addition,
the more N-terminal region 800-1300 may also form a coiled coil. This is in
agreement with the PSI-BLAST result, although this is predicted with a much lower
probability by the COILS program. Interestingly, in the FANCD2 protein coiled coils
are predicted throughout the entire protein. Although this prediction is of a low
probability, a similar result was obtained with the Drosophila Fancd2 ortholog
which is only 23% identical to the human sequence (Fig 2B).
     In summary, the analysis suggests that the N-terminus of FANCD2, but possibly a
more extended region, may form a coiled coil. Although this hypothesis can not be
verified until X-ray structural analysis is performed, the possible homo- or
heterodimerization characteristic for coiled coils may be investigated by
biochemical methods. FANCD2 is not the first example of a DNA repair protein with
a coiled coil domain, since other DNA repair proteins such as the S. pompe Rad18
proteins also contain coiled coils. Possibly, FANCD2 provides some structural basis
that may be required for stabilization of repair intermediates during the handling of
DNA interstrand cross-links.
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(a)
(b)
Fig 2. (A) Homology between FANCD2 and the A. thaliana meprin and TRAF homology domain-containing
protein NP_180104. (B) Prediction of possible coiled coil regions using the COILS program. The COILS
program compares a protein sequence to a databases of known coiled-coils and calculates the probability
that the protein region will adapt a coiled coil conformation. In both human and Drosophila FANCD2 coiled
coils are predicted throughout the entire sequence, in contrast to Arabidopsis protein NP_180104 in which
only C-terminal coiled coils are predicted.
Arabidopsis NP_180104 human FANCD2
Drosophila FancD2
MATH MATH MATH
689 840 944 1310




Highly repetitive myosin heavy chain likePSI-BLAST result:
homology homology
MATH MAD or Smc
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FANCA and FANCC: similar folds as HEAT repeat-like proteins – Since standard BLAST
searches or other pairwise sequence comparison algorithms often fail to detect
similarities when identities fall below ∼30%, enhanced database searching
algorithms have been developed, such as PSI-BLAST that make use of profiles of
related sequences in stead of single sequences. Unfortunately, applying this more
sensitive way of searching also failed for most of the FANC proteins and these
proteins have therefore always been classified as ‘orphan’ proteins. Although it may
not be possible to classify the FANC proteins using PSI-BLAST, we hypothesized that
methods that incorporate structural information during the searching process may
give information about type of fold of the FANC proteins. Unlike the number of
protein sequences, the number of different folds in the protein universe is rather
small (estimated at 1000-8000). This implies that although the FANC proteins have
unique sequences, they are likely to have similar structures as other proteins in the
database. To test this, the mGenThreader server was used which is a modified
version of the original GenThreader fold recognition method [26]. This program
makes use of PSI-BLAST profile and secondary structure prediction as inputs to
enhance sensitivity. In brief, this program predicts whether the sequence and the
predicted secondary structure of the query has significant homology to one or
more entries from the PDB database, which contains all known protein structures.
     To test the reliability of the mGenThreader server, we first tested whether the
FANCG and FANCL proteins could be correctly predicted by the program. As
discussed previously, FANCG is a tetratricopeptide repeat (TPR) protein [14] and
FANCL a RING finger protein (this report). In the PDB database, several structures of
proteins containing these domains are present and the mGenThreader algorithm
should therefore be able to identify a significant similarity. Interestingly, for both
proteins several structures from TPR or TPR-like proteins were found for FANCG at
confidence level ‘certain’ and several structures from RING finger proteins were
found for FANCL at medium to low confidence (Table 1). This indicates that results
from this server may be reliable, although for FANCG one non-TPR structure was
found at confidence level ‘certain’ indicating that results should still be interpreted
with caution.
     All other known FANC proteins, FANCA, -B, -C, -D2, -E, and -F, were then
submitted to the server. Unfortunately, for FANCB and FANCD2 results were
inconsistent, as several different structures were linked to the same protein even
though they were predicted at a high confidence level. Results for FANCE and
FANCF were only of low confidence and were also inconsistent. However, FANCA
and FANCC both showed similarity to several HEAT repeat-containing structures at
high confidence without inconsistencies, indicating that FANCA and FANCC could
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have similar folds as HEAT repeat-containing proteins. The HEAT repeat (huntingtin,
elongation factor 3, A subunit of protein phosphatase 2A, and TOR1) is a unit of a
pair of anti-parallel α-helices that is linked by an intraunit loop. HEAT repeat motifs
vary in length between 37 and 43 residues and occur in tandem arrays forming
superhelical scaffolding matrices that mediate protein-protein interactions but also
modulate the conformation and biological behavior of the proteins with which they
interact [27]. The HEAT repeat family is related to armadillo/β-catenin-like repeats
and it has been noted that many HEAT repeat-containing proteins are involved in
intracellular transport processes.
     In order to evaluate how well the mGenThreader program performs for HEAT
repeat proteins specifically, we tested it for the ATM (Ataxia telangiectasia mutated)
protein. ATM is a large 370 kDa protein with a C-terminal PI3K-like
(Phosphatidylinositol 3-kinase) domain. Outside its highly conserved C-terminal
domain ATM is, similarly as the FANC proteins, only sparsely conserved. In addition,
this region can not be classified into a known protein domain using PSI-BLAST or
Pfam and no repeats are detected by the REP program at a statistically significant
level. However, an elaborate study by Perry and Klecker [28] has found that the
nonkinase portions of ATM and ATM-related proteins such as ATR and TOR are in
fact composed of many HEAT repeats. As expected, the mGenThreader program
predicts a similarity between ATM and several structures containing HEAT repeats,
indicating that the results for FANCA and FANCC should be reliable.
     In conclusion, FANCA and FANCC may have HEAT repeat-like 3D structures. The
putative HEAT repeats in FANCA and FANCC may have a similar function as the
HEAT repeats of ATM or ATR. The HEAT repeats of ATM fold into two main domains
comprising a head and an arm [29]. Upon DNA binding of ATM, the conformation of
the arm domain changes and wraps around the double helix and forms a ring
around the DNA that may be reminiscent of the ‘sliding clamp’ structures such as
PCNA [30]. It can be hypothesized that the putative HEAT-like repeats in FANCA and
FANCC may also be involved in DNA binding and recognize specific structures, such
as stalled replication forks.
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Table 1. mGenThreader results for FANCA, FANCC, FANCG and FANCL
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Note: Per query only a few hits are shown. The FANCA sequence was too large to be submitted at
once to the server.
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Conclusion
For 4 of the FANC proteins analyzed, i.e. FANCL, -D2, -A, and -C, relevant information
was obtained about their domain structures. Unfortunately, no clues were found for
FANCB, FANCE, and FANCF. However, as threading software, used for FANCA and
FANCC, will improve and a more diverse set of structures will become available in
the PDB database, these proteins might become classifiable as well. FANCL is a
member of the RING finger family of proteins, which is in agreement with previous
experimental data. The predictions for FANCD2, FANCA, and FANCC, however, are
less certain but may provide useful starting points for further biochemical studies.
As a putative coiled coil protein, the possible homo- or heterodimerization of
FANCD2 could be tested. The putative HEAT-like repeats may be involved in DNA
binding and the binding of the FA core complex to specific DNA structures such as
stalled replication forks may be experimentally verifiable.
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C H A P T E R
6
Towards a Drosophila melanogaster model
for the Fanconi anemia pathway
anconi anemia (FA) is a recessively inherited genome instability syndrome
characterized by at least 11 complementation groups. To date, 9 FA genes have
been identified and most of their gene products assemble in a multisubunit core
complex which is required to activate the downstream FA protein FANCD2 by
monoubiquitylation. This pathway has evolved relatively recently during evolution,
as only vertebrates posses a full set of FA genes. However, the fruit fly Drosophila
melanogaster possesses two FA genes: the E3 ubiquitin ligase dmFANCL and its
target protein dmFANCD2 indicating that this non-vertebrate may have a ‘basic’
version of the FA pathway, whose characterization may provide novel clues for
understanding the pathway in vertebrates. In a pilot mass spectrometry
experiment, dmFANCL was found to interact with the CAF-1 p105 protein, possibly
linking the FA pathway to chromatin assembly processes. In addition, preliminary
results indicate that Drosophila cells only express the activated dmFANCD2-L
isoform, suggesting that the fruit fly FA pathway could be characterized as ‘always
on’, in contrast to mammalian cells where the activation of FANCD2 seems to be
highly regulated.
Eric Blom, Annette L. Medhurst, Roel C. van der Schors,
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Introduction
Fanconi anemia (FA), a chromosomal instability syndrome characterized by
developmental abnormalities, progressive pancytopenia and cancer predisposition,
is genetically a highly heterogeneous disorder. Cell fusion experiments have
revealed the existence of at least 11 complementation groups (FA-A, B, C, D1, D2, E,
F, G, L, I, and J) and the corresponding genes of 9 complementation groups have
been identified (FANCA, B, C, D1, D2, E, F, G, and L) [1-10]. Biochemical studies have
shown that FANC proteins function in a single pathway and assemble in a large
protein complex [11] that is essential for activation of the downstream FANCD2
protein by monoubiquitylation at Lys561 [5]. This activation is a critical step required
to allow further downstream reactions, such as the association of FANCD2 with
BRCA1 in nuclear repair foci [12]. In spite of a considerable progress in the FA field
[13, 14], the exact function of monoubiquitylated FANCD2 and how this protein
protects the genome against DNA damage such as cross-links is currently not well
understood.
     In this study, we hypothesize that the fruit fly Drosophila melanogaster may be a
helpful model for studying the FA pathway. In contrast to vertebrates, the non-
vertebrate Drosophila melanogaster possesses only two FANC genes, suggesting
that Drosophila might have a ‘basic’ version of the FA pathway. It consists of the E3
ubiquitin ligase dmFANCL and its substrate, dmFANCD2. Since no other core
complex proteins are present in Drosophila, it is unclear how the dmFANCL protein
can perform its task without the help of the core complex. In the mammalian
system, FANCL can not monoubiquitylate FANCD2 in the absence of a functional
core complex. It was hypothesized that other proteins may function as ‘functional
analogs’ in Drosophila and replace the function of the vertebrate core complex.
Therefore, the identification of these putative analogs may be valuable for
understanding the nature and function of the human core complex.
     Our results show that both dmFANCL and dmFANCD2 are expressed at the
mRNA level in the commonly used Drosophila S2 cell line [15]. Currently, antibodies
for these proteins are not available and the expression at the protein level could
therefore not yet be studied. Since large numbers of S2 cells can easily be obtained,
this cell line is an excellent tool for mass spectrometry experiments for which large
amounts of cells are required. In a pilot mass spectrometry experiment, dmFANCL
was found to interact with the chromatin assembly factor 1 subunit p105 protein
(CAF-1 p105). Moreover, preliminary results using a myc-tagged dmFANCD2
construct suggest that dmFANCD2 is only present in its monoubiquitylated form
(dmFANCD2-L) and no dmFANCD2-S is observed. This differs from the situation in
mammalian cells in which both forms are expressed with the FANCD2-S form being
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predominant. If this observation can be verified by further experiments, this may
indicate that the FA pathway in Drosophila, in contrast to vertebrates, is to be
characterized as ‘always on’.
Materials and methods
Cell culture and transfection procedure – Drosophila melanogaster S2 cells [15], a kind
gift from Dr. David Baker (Leiden University Medical Center, The Netherlands), were
grown in Schneider’s insect medium (Sigma) supplemented with 10% heat-
inactivated bovine serum (Gibco) and 5 ml/L Penicillin-Streptomycin (Invitrogen)
without CO2 at 23°C, in closed flasks. To stably transfect cells, exponentially growing
cells were seeded in T-25 cm2 flasks at a concentration of 1 × 106 cells/ml and after
24 hrs were transfected using a calcium phosphate transfection kit (Invitrogen)
according to manufacturer’s instructions. For stable expression of a single construct,
20 µg plasmid DNA of the expression vector (pAc5.1 + insert) and 1 µg DNA of the
selection vector (pCoHygro) was used. For stable expression of two different
constructs, we used 10 µg plasmid DNA of each expression vector and only 0.75 µg
of the pCoHygro plasmid. After 72 hrs, the cells were centrifuged, resuspended in
fresh medium and replated into the same flask and after 96 hrs cells were selected
in medium containing 300-400 µg/ml Hygromycin B (Roche or Invitrogen) until
resistant cells appeared (typically after 2 weeks).
Constructs – A cDNA clone containing full-length Drosophila melanogaster
dmFANCD2 was a kind gift from Dr. J. Surrallés (Universitat Autònoma de Barcelona,
Spain). Since no antibodies were available for the dmFANCD2 protein, a N-terminal
c-myc tag was added and cloned into the pAc5.1 expression vector (Invitrogen).
Since the cDNA was not available for dmFANCL and technical difficulties impeded
the cloning of the cDNA, the genomic sequence was obtained by PCR on genomic
DNA isolated from S2 cells. An N-terminal flag-tag was then added to the first exon
and the construct was cloned into the pAc5.1 expression vector. It was expected
that S2 cells were able to correctly splice this construct because the intron
sequences were left intact. In the human system, for both FANCD2 and FANCL
proteins an N-terminal tag is known not to interfere with protein functionality. In
addition, a C-terminal V5- and His-tagged construct that contained exon 2 of
dmFANCL (encoding the majority of the protein, see figure 1) was prepared in the
same vector. This construct was used in the mass spectrometry experiment.
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RT-PCR dmFANCL and dmFANCD2 – Total RNA was extracted from S2 cells using
TRIzol reagent (Invitrogen). First-strand cDNA synthesis was then performed using
SuperScript II reverse transcriptase (Invitrogen) according the manufacturer’s
instructions. An aliquot of the synthesized cDNA was then amplified using a
standard PCR reaction with an annealing temperature of 58°C and 35 cycles on a
Robocycler 96 (Stratagene). The following primers were used: dmFANCL-F:
TCAGCCAAGTGGAGCGTGCAT, dmFANCL-R: CACTTGCAGGCAGTACTCGTT,
dmFANCD2-F: GAGCGAGTGGAGTGATAAGT, and dmFANCD2-R: GCTTTGTCCTTCGTA-
TTCAG.
Mass spectrometry experiment – S2 cells were stably transfected with the C-terminal
V5- and His-tagged dmFANCL-exon2 plasmid. As a negative control, S2 cells were
transfected with a LacZ plasmid with identical C-terminal V5- and His-tags.
Approximately 5 × 109 cells were propagated and a nuclear extract was prepared
using a similar procedure as previously described [16, 17]. The nuclear pellet was
then lysed in 40 ml NP-40 lysisbuffer containing 10% glycerol (50 mM Tris-HCl,
pH7.5, 150 mM NaCl, 1% NP-40, 10% glycerol, 500 µg/ml Pefabloc, 1 µg/ml
apoprotinin, 1 µg/ml pepstatin, 1 µg/ml leupeptin) and sheared through a 19-
gauge needle. The lysate was then clarified by centrifugation at 4°C, after which α-
V5 and α-His(C-term.) antibodies (both from Invitrogen) were added and incubated
overnight at 4°C with continuous mixing. The following day, the immune
complexes were collected by adding protein A sepharose CL-4B (Amersham
Biosciences) for 2 hours at 4°C with mixing. The beads were then washed with lysis
buffer and the samples were run on a standard 10% polyacrylamide SDS gel
electrophoresis (Hoefer SE 400) gel system. The gel was fixed in 50% ethanol/3%
phosphoric acid overnight, washed 3 times for 15 min in MilliQ water, and stained
with Coomassie brilliant blue G-250 solution (Sigma) for 24 hours. Bands were
excised from the gel and analyzed using mass spectrometry. Note that in this type
of experiment the amount of lysis buffer was critical for the observed level of
background. When too small a volume is used, the protein concentration becomes
too high causing an aspecific polymerization and precipitation of proteins. These
precipitated proteins become trapped within the beads and can not be removed
during the washing step of the beads [18]. The experiment was first optimized with
fewer cells and the gels were stained with the more sensitive silver-staining method
instead (Invitrogen SilverQuest staining kit).
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Immunoblotting and coimmunoprecipitation – Immunoblotting samples were lysed
in 2× sample buffer (80 mM Tris-HCl pH 6.8, 0.8% sodium dodecyl sulfate, 100 mM
dithiothreitol (DTT), 4% glycerol, 0.4% bromphenolblue), boiled for 5 min and
subjected to standard polyacrylamide SDS gel electrophoresis. After transfer to an
Immobilon-P membrane (Millipore), α-V5 (1:5000, Invitrogen) was used as primary
antibody and goat α-mouse-HRP (1:2000, DAKO) as secondary antibody after which
the blot was developed using the ECL Western blotting system (Amersham
Biosciences).
     For coimmunoprecipitation total cell extracts, prepared in lysis buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 500 µg/ml Pefabloc, 1 µg/ml apoprotinin, 1
µg/ml pepstatin, 1 µg/ml leupeptin), were incubated with α-V5 antibody or with α-
flag M2 resin (Sigma) 2 h or overnight, at 4°C. When α-V5 antibody was used,
protein A beads were added afterwards and incubated at 4°C for 30 min. After
washing the beads in lysis buffer, 2× sample buffer was added and boiled for 5 min.
The samples were then run on a standard polyacrylamide SDS gel electrophoresis
and analyzed by immunoblotting.
Monoubiquitylation of dmFANCD2 – S2 cells, stably transfected with either flag-
tagged dmFANCL and myc-tagged dmFANCD2 or myc-tagged dmFANCD2 alone,
were seeded at a concentration of approximately of 1 × 106 cells/ml in the presence
of 1 or 2 µM final concentration mitomycin C (MMC) or 2 mM final concentration
hydroxyurea (HU) or cells were gassed with O2 or N2. The following day, 0.5 ml cell
suspension was collected and washed once in PBS after which the cell pellet was
lysed in 2× sample buffer, then heated at 95°C for 5 min, followed by a standard
6.5% SDS gel electrophoresis after which the proteins were transferred to an
Immobilon-P transfer membrane (Millipore) in transfer buffer (25 mM Tris-HCl, 200
mM glycine, 15% methanol) at ~80 mA overnight at 4°C. After blocking in 5% (w/v)
non-fat dry milk in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.2% Tween-20) the blot
was incubated in primary antibody (α-myc, Invitrogen), washed 3 times in TBST,
then incubated in secondary antibody (goat α-mouse HRP, DAKO) and washed 5
times in TBST after which the ECL Western blotting analysis system (Amersham
Pharmacia) was used to develop the blot.
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Results
Evolutionary conservation of dmFANCL – Unlike other FA core complex members,
FANCL is conserved in the non-vertebrate D. melanogaster. Drosophila FANCL is a
381 residue protein named CG12812 in the database and no experimental studies
have yet been published. Overall, the protein is poorly conserved with a percentage
identity of only 22% and a percentage similarity of 35%, which is close to the
detection limit of database search programs. The RING domain, however, is much
more conserved (Fig. 1) suggesting that it has maintained its ubiquitin ligase
activity during evolution. In order to exclude the possibility that the protein
CG12812 is just a random protein sharing a similar C-terminal RING domain, a PSI-
BLAST search was performed using the Drosophila sequence without the RING
domain. As expected, statistical significant homologies between dmFANCL, human
FANCL and several other vertebrate FancL sequences were found. In addition, no
statistical significant homology was found to any other protein in the database,
verifying that the sequences found are true orthologs. Furthermore, although
suggested by Meetei et al. [9] no evidence was found for the presence of possible
WD40 repeats in the N-terminus in our analysis. On the genomic level, dmFANCL is
encoded by 3 exons with 2 small introns of about 55 bp each. The central exon 2
encodes the majority of the protein. The exon boundaries are indicated in figure 1.
dmFANCL   1 MESNEDVERLLCQKYPGLAAELQPSGACIIRGVLGSEDTWRRLKLYLPHHPALHGFQLYV
human FANCL   1 ---MAVTEASLLRQCPLLLPQNRSK--TVYEGFISAQGRDFHLRIVLPEDLQLKNARLLC
dmFANCL  61 QESLEYKLY---TSANLKLQDDWLLEDFLDHLPKILP-AQKAPTVPKELCREGNIYYDIL
human FANCL  56 SWQLRTILSGYHRIVQQRMQHPPDLMSFMMELKMLLEVALKNRQELYALPPPPQFYSSLI
dmFANCL 117 ALYKSN--EYCLQVDEACSMIRFS-EFTDFEQHYLELKIPSLLLLDHS--LPDCVSLGEM
human FANCL 116 EEIGTLGWDKLVYADTCFSTIKLKAEDASGREHLITLKLKAKYPAESPDYFVDFPVPFCA
dmFANCL 172 LTKSAGNLEEALNLFRKLLEDLRPFYDNFMDIDELCHVLQPSPISSKHKTRLFPLKDRVY
human FANCL 176 SWTPQSSLISIYSQFLAAIESLKAFWDVMDEIDEKTWVLEPEKPPRSATARRIALGNNVS
dmFANCL 232 LKLTIADPFACIASMSLKIIGPTEEVARLRHVLSDGLSNWDSEMNIHKNLLRMFDLCYFP
human FANCL 236 INIEVDPRHPTMLPECF-FLGADHVVKPLGIKLSRNIHLWDPENSVLQNLKDVLEIDFP-
dmFANCL 292 MPDWSDGPKLDEEDNEELRCNICFAYRLDGGEVPLVSCDNAKCVLKCHAVCLEEWFKTLM
human FANCL 294 ------ARAILEKSDFTMDCGICYAYQLDG-TIPDQVCDNSQCGQPFHQICLYEWLRGLL
dmFANCL 352 DGKTFLEVSFGQCPFCKAKLSTSFAALLND
human FANCL 347 TSRQSFNIIFGECPYCSKPITLKMSGRKH-
Fig. 1. Comparative sequence analysis of dmFANCL and its human ortholog. Identical residues are indicated
in black and similar residues in gray (BoxShade program). Exon boundaries and the RING domain are
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Expression of dmFANCL and dmFANCD2
In order to determine whether dmFANCL and dmFANCD2 are expressed in
Drosophila S2 cells, RT-PCR was performed on total RNA with primers that anneal in
different exons. Despite a considerable genomic DNA contamination in the RNA
preparation, it was evident that for both dmFANCL and dmFANCD2 smaller PCR
fragments derived from mRNA were present (Fig. 2). This indicates that dmFANCL
and dmFANCD2 are expressed in S2 cells and that this cell line may be used as a tool
for studying the FA pathway in Drosophila. Since no antibodies were available,
expression of these gene products on the protein level could not be studied.
Fig. 2. Expression of dmFANCL and dmFANCD2 mRNAs in the Drosophila melanogaster S2 cell line as shown
by RT-PCR technique.
Pilot experiment mass spectrometry of dmFANCL-interacting proteins – S2 cells were
stably transfected with C-terminal V5- and His-tagged dmFANCL-exon2 plasmid that
expressed almost the entire protein (Fig. 1). This construct was chosen because a
full-length cDNA clone was not available. In addition, the α-V5 antibody performed
very well on direct western blot and in immunoprecipitation experiments showing
a strong signal without any background, indicating this antibody is a suitable tool
for the intended experiment. As a negative control, the cell line was stably
transfected with a plasmid containing LacZ with same C-terminal V5- and His-tags.
After immunoprecipitation, running and staining the gel, several differences
between the negative control and dmFANCL-exon2 construct were evident
indicating that several proteins were interacting specifically to the two dmFANCL
constructs. The pattern observed was identical between independent experiments;
a representative experiment is shown in figure 3. Protein bands that were identical
in both lanes were considered as proteins that aspecifically bind to the beads. Four
bands that were different for the dmFANCL-exon2 construct in the range of 70-110
kDa were excised and analyzed by mass spectrometry (Fig 3). Band 3 and 4 were
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possibly caused by the fact that the constructs were overexpressed. In addition,
band 2 could not be analyzed due to a low signal strength. Band 1 was identified as
chromatin assembly factor CAF1-p105. Although this identification was at a low
confidence level due to a low signal strength, the size of the excised band (~110
kDa) matches the predicted size of the protein identified (105 kDa) indicating that
this result could be reliable.
Fig. 3. Silver-stained gel showing the result of the LacZ and dmFANCL-exon2 coimmunoprecipitation
experiment. The four protein bands that were analyzed by mass spectrometry and the immunoglobin heavy
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Protein interaction network of dmFANCL – In an elaborate study, Giot et al. [19]
recently published a two-hybrid-based protein interaction map of the fruit fly
proteome. From a total of 10,623 predicted transcripts, 7048 proteins were found to
interact in 20,405 different interactions and this draft map was later refined to a
higher confidence map of 4679 proteins and 4780 interactions using computational
methods. In their dataset, 8 interactions are present for dmFANCL (table 1) and
none for dmFANCD2. A protein interaction map based on the refined dataset is
shown in figure 4. From the 8 interactions 2 interacting proteins, a novel E2 ligase
and the DNA polymerase α-73 [20], seemed interesting and were therefore
experimentally tested using the different coimmunoprecipitation technique. Both
cDNAs were cloned by PCR and a C-terminal V5- and His-tagged plasmid was
prepared for both (pAc5.1 vector). This plasmid was stably cotransfected with a N-
terminal flag-tagged dmFANCL(genomic) construct in S2 cells. Unfortunately, no
interaction was found using an α-V5 immunoprecipitation experiment although
both constructs were expressed at high levels (Fig. 5). In addition, in a mammalian-
two-hybrid pilot experiment with human FANCL and the human counterparts for
the E2 ligase and DNA polymerase also no interactions were found (data not
shown). The other 6 interacting proteins from the dataset have not been tested to
date.
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Activation of the FA pathway in S2 cells – In the mammalian system,
monoubiquitylation of FANCD2 is a hallmark feature of an activated FA pathway. In
order to serve as a model for FA, S2 cells should have a similar activation of
dmFANCD2. Although this is likely since its E3 ligase dmFANCL is conserved and the
monoubiquitylation site is preserved as well [22], this was not yet verified
experimentally. An N-terminal myc-tagged dmFANCD2 construct was expressed in
S2 cells. In the mammalian system, a N-terminal tag is known not to interfere with
protein functionality of FANCD2. Interestingly, under conditions known to induce
monoubiquitylation in mammalian cells, such as treatment with mitomycin C or
hydroxyurea, only one band was observed (Fig. 6A). Is was hypothesized that the
endogenously expressed dmFANCL in S2 cells may not be sufficient to
monoubiquitylate the overexpressed myc-dmFANCD2 construct. The cells were
therefore cotransfected with the flag-dmFANCL(genomic) construct. Unexpectedly,
this cotransfection induced an additional smaller band than observed when myc-
dmFANCD2 is expressed alone (Fig. 6B). This may indicate that the flag-
dmFANCL(genomic) construct may act as an inhibitor instead. When this construct
is not spliced, the two introns of about 55 bp each remain in-frame and a slightly
larger protein is then encoded, which may act as a dominant negative. The above
result may suggest that unlike mammalian cells where FANCD2-S and FANCD2-L
are both present, S2 cells express only dmFAND2-L.
Fig. 4. Protein network of dmFANCL as visualized using Osprey software [21]. All nodes were removed that
were more than 2 nodes away from dmFANCL and the putative E2 ligase. Only high confidence interactions
are shown. Note that the putative E2 ligase interacts with 3 different E3 ligases: CG32581, CG8974 and
dmFANCL. In addition, the E3 ligases CG32581 and CG8974 also interact with three other E2 ligases, UbcD2,
UbcD4 and eff, suggesting a redundancy within the network.
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Fig. 5. Coimmunoprecipitation of flag-dmFANCL(genomic) and C-terminal V5-tagged E2 ligase or DNA
polymerase. As negative control C-terminal V5-tagged LacZ was used. (A) Direct western blot showing that
the LacZ, putative E2 ligase, and DNA polymerase α-73 constructs are expressed. (B) Immunoprecipitation
using α-V5 antibody followed by α-flag M2 Western blot. The position at which the protein expressed from
the flag-dmFANCL(genomic) construct was expected is indicated by an asterisk.
Discussion
Although preliminary, the data in this study may give some interesting insight in
the FA pathway in Drosophila cells. The pilot mass spectrometry experiment
suggests that dmFANCL may interact with chromatin assembly factor CAF-1 p105.
This is a subunit of a protein complex, named CAF-1, which also contains the p180,
p75 and p55 subunits. In human and yeast cells the CAF-1 complex is composed of
only three subunits. CAF-1 p105 is a protein of 747 residues with an apparent
molecular weight of 105 kDa with several N-terminal WD repeats and a central PEST
domain [23]. CAF-1 participates in the assembly of newly synthesized DNA into
chromatin during replication but also during DNA repair. Interestingly, CAF-1
interacts with the PCNA component of the DNA replication and repair machinery
and both are recruited at sites of DNA lesions and may be involved in sensing of
DNA damage [24].
     Further optimization of the experiment may reveal several additional proteins
that interact with dmFANCL. Increasing the amount of cells may enhance the
detection of weaker bands, specifically the ones from smaller proteins. These
proteins are less intensively stained by either silver- or Coomassie-staining, biasing
the experiment towards the larger proteins. In this experiment, 5 × 109 cells were
used, but this number can be increased. This amount corresponds to a culture
volume of approximately 400 ml.
     Three different proteins are required for ubiquitylation reactions: E1, E2, and E3
ligases. For the FA pathway, the E1 and E2 ligases are currently unknown. It was
hypothesized that the E2 ligase found by Giot et al. [19] which interacts with
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Unfortunately, this interaction was not substantiated by a coimmunoprecipitation
experiment, indicating that the interaction may be too weak or too transient to be
detected with this technique. A RNAi experiment may therefore give a more
decisive clue to this question. Although the two-hybrid interaction between DNA
polymerase α-73 and dmFANCL was considered as a low confidence interaction
(table 1), this interaction was attempted to confirm using coimmunoprecipitation.
In yeast this polymerase is involved in the initial stage of DNA replication [25]. Since
activated FANCD2 is expressed during S-phase in mammalian cells, it was
speculated that these proteins may be functionally related. Unfortunately, no
interaction could be demonstrated.
     The monoubiquitylation experiment yielded a highly unexpected result. It was
postulated that in Drosophila both dmFANCD2-S and dmFANCD2-L are present,
similar to what is observed in mammalian cells. However, the results indicated that
dmFANCD2-L is expressed suggesting that in Drosophila the pathway may be
characterized as ‘always on’. This suggests that the vertebrate core complex may
have been evolved to regulate the monoubiquitylation of FANCD2 in vertebrate
cells. Clearly, further experimentation is needed to address this issue more
rigorously.
Fig. 6. Monoubiquitylation of N-terminal myc-tagged dmFANCD2 stably expressed in S2 cells. (A) Myc-
dmFANCD2 construct expressed in S2 cells gives only one band for dmFANCD2. In addition, at the various
conditions tested no induction of other isoforms was detected. (B) Induction of a smaller additional
dmFANCD2 isoform by stably coexpressing the dmFANCL(genomic) construct, which possibly functions as a
dominant negative construct (see text). For comparison, the air sample from the experiment of figure A was
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Fanconi anemia (FA) is a recessively inherited disorder that was first described in
1927 by the Swiss pediatrician Guido Fanconi. The disease is characterized by
aplastic anemia, cancer predisposition (mainly acute myeloid leukemia and
squamous cell carcinoma) and diverse congenital anomalies including absent
thumbs and radii. Mainly due to the bone marrow failure as well as the cancer risk
the mean life expectancy is low, generally 20 years or less. In addition to supportive
therapy, bone marrow transplantation is the most important treatment at present.
     FA is genetically a highly heterogeneous disease with at least 11 different genes
expected to be involved. From these putative 11 genes, 9 have been identified:
FANCA, B, C, D1, D2, E, F, G, and L. Biochemical studies have revealed that FANC
proteins function in a single pathway. In this pathway, most FANC proteins (FANCA,
B, C, E, F, G, and L) assemble in a nuclear complex – termed the FA core complex –
that is required for activation of the FANCD2 protein by monoubiquitylation at
Lys561. This activation is essential for further downstream reactions such as the
association of FANCD2 with the BRCA1 protein in nuclear repair foci. The FANCD1
gene product, which is identical to the BRCA2 protein, is thought to function
downstream of FANCD2 activation and is not required for monoubiquitylation of
this protein.
     Since FA cells are hypersensitive to agents that induce DNA interstrand cross-
links (ICLs), the FA biochemical pathway is thought to be involved in the repair of
this type of damage. Interestingly, the DNA interstrand cross-link is one of the most
toxic types of DNA damage and if left improperly repaired could result in cell death
or cancer. However, the exact role of the FANC proteins in the repair process of ICLs
is not well understood. An important reason for this is the fact that the FANC
proteins are ‘orphan’ proteins. In contrast to most other gene products, the FANC
proteins are novel proteins that are very limitedly conserved during evolution and
do not show any homology to other proteins in the database. This makes an in silico
prediction of their biochemical function impossible. To investigate this matter, the
aim of this thesis was to study the FANC protein sequences in other vertebrates,
such as chicken, clawed frog and zebrafish. Amino acids that have remained
identical during evolution are likely to be functionally important and in potential
could provide important clues about the molecular action of these proteins.
     In chapter 2 the principle of orphan proteins and protein domains is further
explained and discussed how a bioinformatic approach could provide important
clues about the molecular function of gene products. In a preliminary analysis,
FANCG was found to represent a member of the tetratricopeptide repeat (TPR)
containing proteins. This was further studied in chapter 3 and a total of 7 TPRs
motifs in FANCG were identified. The TPR motif is an important protein-protein
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interaction motif and often plays a role in the assembly of multisubunit protein
complexes. Mutation experiments revealed that the TPRs in FANCG are essential for
a functional pathway and were confirmed to function as protein-protein interaction
modules. In chapter 4, the FANCF protein was studied using the approach
described in chapter 2 but no protein domain was identified. However, an extensive
biochemical study indicated that this protein is likely to function as an adaptor
molecule in the FA core complex. The N-terminus is required for binding of the
FANCC/FANCE subcomplex and the C-terminus interacts with FANCG. The other
FANC protein sequences were studied in chapter 5. Evidence was found that
FANCA and FANCC are both members of the HEAT-repeat containing proteins and
are therefore predicted to be involved as scaffolds in the assembly of the FA core
complex, similarly to FANCG. Moreover, the FANCD2 protein is likely to represent a
myosin heavy chain-like molecule and FANCL was found to contain a RING domain
rather than a PHD domain, as previously reported by others. The presence of a RING
domain in FANCL strongly suggests that this protein harbors the catalytic activity
required for the monoubiquitylation of FANCD2.
     The FA pathway in the fruit fly Drosophila melanogaster was studied.
Interestingly, the fruit fly genome contains only two FANC genes: the upstream
catalytic subunit dmFANCL and its substrate dmFANCD2, suggesting that this
species harbors a more elementary FA pathway. It could therefore provide a more
simple model for studying FA and may also help to explain the purpose of the
multisubunit core complex as found in vertebrates. Preliminary results are
presented in chapter 6.
     The results in this thesis suggest that for many orphan proteins it may be
possible to ‘de-orphanize’ and classify them into a known protein domain family.
FANCG was identified as a member of the TPR-containing proteins, FANCA and
FANCC are likely HEAT-repeat proteins, and FANCD2 may be a myosin heavy chain-
like protein. This suggests that most orphans have arisen by duplication from an
ancestral gene, as assumed in chapter 2. An alternative mechanism, the recruitment
of randomly occurring open reading frames during evolution, may be therefore be
of less importance. Development and application of more sensitive database
searching algorithms may result in a decrease of the number of orphans in the
database. At present, it is estimated that 10-30% of all predicted open reading
frames in fully sequenced genomes are orphans.
     Except for FANCL, none of the FANC core complex subunits appears to contain a
catalytic domain. Therefore, the overall quaternary structure, possibly in
combination with conformational changes during activation of the FA pathway, is
likely to represent the most important feature of the FA core complex. There may
Summary and discussion        119
exist an important similarity between the FA core complex and the ATM protein.
The ATM protein is a large protein of 3056 amino acids that is almost entirely
composed of HEAT repeats except a small C-terminal PI3-kinase domain. Single-
particle electron microscopy experiments by Llorca et al. (2003) revealed that the
tertiary structure of ATM is composed of a ‘head’ and an ‘arm’ domain. Upon DNA
binding of ATM, the conformation of the arm domain changes and wraps around
the double helix and forms a ring fixing ATM around the double stranded DNA
helix. The FA core complex may function in a similar way: the large quaternary
structure of the complex may recognize a particular DNA structure, possibly a
stalled replication fork or another DNA repair intermediate. Binding of the complex
to this structure may then induce a conformational change and release the E3 ligase
activity of FANCL resulting in monoubiquitylation of FANCD2 and activation of the
FA pathway. In the near future, X-ray crystallography or single-particle electron
microscopy techniques may give further insight into the function of the FA
biochemical pathway and how this pathway protects the genome from DNA
damage.
Evolution of the FANC core complex proteins: a novel mode of persistent rapid
evolution? – In the previous chapters using a bioinformatic approach to assess the
molecular function of the FANC gene products [Chapters 1–5], it was observed that
the FANC proteins are considerably less conserved than average proteins in
vertebrate species (Table 1). With fewer than 70% sequence identity between
human and mouse, FANC proteins are amongst the 10% fastest evolving proteins
[1, 2]. However, normal expectations based on evolutionary biology predict that a
protein with a critical function should have a highly conserved sequence in order to
maintain that function. Given the strong disadvantageous phenotype in humans,
mice, and zebrafish when one of the FANC genes is absent or mutated [3–5], the
extraordinarily high divergence between human, mouse, chicken and zebrafish
FANC sequences is therefore unexpected.
     Estimating the rate of non-synonymous substitutions (Ka) versus that of
synonymous substitutions (Ks) between coding sequences of closely related species
using algorithms such as the K-Estimator program [6], may give insight to the
selective forces that act on an evolving protein coding region. A protein coding
region, such as a recently duplicated gene, that not (yet) supports a vital function
(‘relaxed constraint’) will evolve neutrally, with a Ka/Ks ratio ≈ 1. Most genes,
however, have already acquired an essential function and most amino acid
substitutions will therefore be detrimental and these genes will evolve under
negative selection (Ka/Ks << 1). Positive selection, as indicated by Ka/Ks > 1, occurs
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when protein functionality is not optimal anymore due to a changing environment
and indicates that a protein coding region is under adaptive evolution.
Table 1. Estimation of the percentage identity between the human FANC proteins and their












FANCA 1455 66 ~46 ? -
FANCB 859 ~49 ~42 ~25 -
FANCC 558 67 49 ~28 -
FANCD2 1471 75 56 53 23
FANCE 536 ~61 ~38 ~30 -
FANCF 374 ~49 ? 31 -
FANCG 622 72 36 26 -
FANCL 375 79 70 59 22
Histone H4 103 100% 100% 100% 98%
Cytochrome C 105 91% 87% 84% 78%
Hemoglobin α 142 86% 70% 56% -
Note that ~ indicates that the estimation was based on a partial sequence only. For reference, three examples
are given of proteins with various rates of evolution [7].
     The Ka/Ks ratio for all FANC proteins is about 0.35 (Table 2) Although disease
genes have previously been reported to have elevated Ka/Ks ratios compared to
nondisease genes [8, 9], the Ka/Ks ratios of the FANC genes are significantly higher
than for ‘average’ disease genes. Moreover, the higher than average Ka/Ks ratios are
in agreement with the observed low percentage identities between human and
mouse FANC protein sequences. As the actual numbers of neutral and adaptive
substitutions can not be measured, the high Ka/Ks ratio of 0.35 can be attributed to
either a relatively weak purifying selection (relaxed constraint) or to adaptive
evolution of the FANC genes.
     Biochemical data support the hypothesis that the FANC gene products have
been evolving under both a weak purifying selection as well as adaptive evolution.
Since no phenotypic difference exists between FA patients from the various
complementation groups, all FANC genes acting upstream of FANCD2 are known to
be genetically epistatic. This indicates that the FA core complex itself is the
‘functional unit’ rather than the individual subunits. It has now been widely
recognized that protein complexes are important functional units in cellular
biochemistry. It can be speculated that in a highly iterative scenario, the individual
subunits rapidly change over time but the overall structure and function of the core
complex is maintained (Figure 1). In the ‘first round’, at interacting surfaces several
substitutions that are neutral or nearly-neutral will accumulate. However, after
these substitutions have occurred the interacting surfaces may be ‘re-optimized’ in
one or more subunits in the second round, possibly during a brief period of positive
selection. In the third round additional (nearly) neutral substitutions are gathered
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which will then again become compensated in the fourth round. And so on. In this
system it becomes evident that amino acid positions that are functionally constraint
in the first round may become neutral after a few rounds of evolution, and vice
versa. This phenomenon has previously been described in the covarion model
[reviewed in refs 10 and 11].
Table 2. Estimation of substitution rates of the FANC genes



































































































Mouse Fanca, -c, and -g orthologs can act as substitutes for their human
counterparts, despite their low levels of identity of 66–72% with human [12–14].
This indicates that a high fraction of neutral substitutions must be possible. On the
other hand, the Xenopus laevis Fancf and zebrafish Fancg proteins (27% and 26%
identity with human) are not able to substitute their human core complex
components [15, E. Blom unpublished result] showing that Xenopus and zebrafish
FANC protein 3D structures are significantly different from human. This altered
structure must be compensated in one or more other FANC core complex subunits
and brief moments of adaptation must have occurred in order to maintain the
overall function of the complex during evolution. Furthermore, the conservation of
the overall structure and function of the FANC core complex has been illustrated in
zebrafish. Fancd2-deficient zebrafish can be corrected by injection of the human
FANCD2 mRNA [5]. This indicates that the zebrafish core complex accurately
recognizes its human FANCD2 ortholog and activates it accordingly to result in
restoration of the FA pathway.
     The scenario presented here appears to be similar as for previously reported
compensated pathogenic deviations (CPDs) [16, 17]. It has been shown that
mutations that are known to be pathogenic in one species occasionally become
fixed in a phylogenetic closely related species. For such mutation to become the
wild type sequence, second-site or compensatory mutations must have co-evolved.
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Although it has been suggested that intramolecular compensation predominates
for CPDs [17], it is likely that for the FANC core complex evolution intermolecular
compensation must have contributed greatly.
Fig. 1. Model of the human and zebrafish FANC core complexes, composed of the subunits FANCA, -B, -C, -E,
-F, -G, and -L. The FANCL subunit contains the enzymatic RING domain that is required for activation of
FANCD2 by monoubiquitylation. The black lines indicate that the overall shape and structure remains
identical during evolution whereas the interacting surfaces between each subunit (grey lines) evolve rapidly
and are highly different between human and zebrafish.
     The above evolutionary scenario of the FANC complex may be important for
several reasons. Firstly, it may well be of relevance for other protein complexes.
Although most protein complexes contain several highly conserved domains, the
protein-protein interaction regions may be subjected to the same mode of rapid
evolution as shown for the FANC genes. Secondly, the model presented here may
help to explain how ‘orphan genes’ arise during evolution. Orphan proteins are
gene products that have no detectable similarity to other proteins in the database.
Interestingly, FANCA, -B, -C, -E, and -F are currently all classified as orphans. In
contrast to neutral (relaxed constraint) and adaptive evolution, which may only
occur for a brief period during the history of an evolving protein [18], the scenario
proposed here is intrinsically ‘endless’. Assuming that the FANC genes all have
arisen from duplication from an ancestral gene, the phenomenon of intrinsic
continuity of change may explain why for the FANC genes the homology with their
ancestral gene or paralog has been lost, in contrast to non-orphan genes which
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Het ontrafelen van de FA biochemische route
Onderzoek op het grensvlak van biochemie, moleculaire evolutiebiologie en
bioinformatica
Fanconi anemie (afgekort FA) is een erfelijke ziekte die in 1927 voor het eerst
beschreven werd door de Zwitserse kinderarts Guido Fanconi. De aandoening
Fanconi anemie kenmerkt zich door een zeer ernstige vorm van bloedarmoede, een
sterk verhoogd risico op het krijgen van kanker (voornamelijk acute myeloïde
leukemie en plaveiselcel-carcinoom) en aangeboren afwijkingen zoals het
ontbreken van de duim. Het falen van het beenmerg om voldoende bloedcellen
aan te maken en het verhoogde kankerrisico maken dat FA patiënten gemiddeld
niet ouder worden dan 25 jaar. Op dit moment is de belangrijkste vorm van
therapie voor FA patiënten de beenmergtransplantatie, maar dit kan de ziekte
helaas niet volledig genezen.
     FA is genetisch zeer heterogeen, wat wil zeggen dat op dit moment
aangenomen wordt dat tenminste 11 genen een rol spelen bij het ontstaan van de
ziekte. Van deze 11 genen zijn er reeds 9 geïdentificeerd: FANCA, B, C, D1, D2, E, F, G,
en L. Biochemische studies hebben aangetoond dat the FANC genproducten met
elkaar samenwerken in één biochemische ‘route’. In dit proces verzamelen zich de
meeste FANC eiwitten in een eiwitcomplex (dat zijn FANCA, B, C, E, F, G en L) wat
het FA kerncomplex genoemd wordt. De aanwezigheid van dit complex is
vervolgens verantwoordelijk voor de activatie van het FANCD2 eiwit door
monoubiquitylering van het aminozuur Lysine561. Deze activatie induceert volgende
biochemische reacties zoals associatie van FANCD2 met het BRCA1 eiwit in ‘nuclear
repair foci’. Het FANCD1 eiwit, dat hetzelfde is als het borstkanker genproduct
BRCA2, speelt ook een rol in de FA biochemische route maar dit eiwit komt
waarschijnlijk pas in actie na de activering van FANCD2.
     Omdat cellen van FA patiënten hypergevoelig zijn voor stoffen die een covalente
binding veroorzaken tussen de twee ketens van de dubbele DNA helix (‘DNA
interstrand cross-link’), wordt algemeen aangenomen dat de FA biochemische
route een belangrijke rol speelt bij de reparatie van dit type DNA schade.
Opmerkelijk is dat de DNA interstrand cross-link één van de meest schadelijke
vormen van DNA schade is en, indien niet op een juiste manier gerepareerd, kan
leiden tot het afsterven van de betreffende cel of tot ontstaan van kanker. Op dit
moment is echter nog onduidelijk op welke wijze de FANC eiwitten bijdragen aan
het reparatieproces van deze DNA interstrand cross-links. Een belangrijke reden
hiervoor is dat de FANC eiwitten zogenaamde ‘wees’-eiwitten zijn. In tegenstelling
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tot de meeste andere genproducten lijken de FANC eiwitten compleet ‘nieuwe’
eiwitten. Ze zijn slecht geconserveerd tijdens de evolutie en vertonen geen enkele
overeenkomst met andere eiwitten in de database. Het is daarom onmogelijk om
op voorhand door middel van het toepassen van bioinformatica te voorspellen
welke biochemische functie de FANC eiwitten hebben. Om dit probleem op te
lossen werden de FANC eiwitsequenties in andere gewervelde diersoorten zoals
kip, klauwpad en zebravis onderzocht. Tijdens de evolutie identiek gebleven
aminozuren zijn waarschijnlijk belangrijk voor de functie en kunnen mogelijk
inzicht geven in de moleculaire functie van de FANC eiwitten.
     In hoofdstuk 2 wordt het principe van ‘wees’-eiwitten en dat van
geconserveerde eiwitdomeinen verder uitgelegd. Verder wordt in dit hoofdstuk
besproken hoe het toepassen van bioinformatica kan leiden tot meer inzicht in de
functie van eiwitten. Uit een eerste analyse bleek dat FANCG toch geen weeseiwit is
maar deel uitmaakt van de familie van tetratricopeptide repeat (TPR) eiwitten. Dit
werd verder onderzocht in hoofdstuk 3, waarin in totaal 7 TPR motieven in het
FANCG eiwit worden geïdentificeerd. Het TPR motief is een belangrijke eiwit-eiwit
interactie module, die vaak een belangrijke rol speelt in de assemblage van
mulitsubunit eiwitcomplexen. Mutatie-analyse experimenten tonen aan dat de TPR
motieven in FANCG essentieel zijn voor een goed functioneren van de FA
biochemische route en bevestigen dat deze motieven inderdaad nodig zijn voor
eiwit-eiwit interacties. In hoofdstuk 4 werd het FANCF eiwit bestudeerd maar in de
sequentie werd geen eiwitdomein gevonden. Een uitgebreide biochemische studie
toont echter aan dat dit eiwit waarschijnlijk functioneert als ‘adaptor’-molecuul in
het FA kerncomplex. De overige FANC eiwitsequenties werden bestudeerd in
hoofdstuk 5. Aanwijzingen werden gevonden dat FANCA en FANCC beide deel
uitmaken van de familie van HEAT-repeat eiwitten. Op basis van dit gegeven is het
aannemelijk dat FANCA en FANCC – net als het FANCG eiwit – een belangrijke rol
spelen bij de assemblage van het FA kerncomplex. Verder werd bewijs gevonden
dat FANCD2 waarschijnlijk dezelfde eigenschappen bezit als dat van coiled-coil
eiwitten. In tegenstelling tot wat is voorgesteld in een publicatie van Meetei et al.
(2003) heeft het FANCL eiwit geen PHD-finger domein maar in plaats daarvan een
RING-domein. Door de aanwezigheid van dit RING-domein bezit FANCL een E3
ligase enzymatische activiteit en is het in staat om FANCD2 te monoubiquityleren.
     De FA biochemische route werd bestudeerd in de fruitvlieg Drosophila
melanogaster. Bijzonder is dat het genoom van de fruitvlieg slechts twee FANC
genen bevat: het enzymatische gedeelte van het FA kerncomplex dmFANCL en het
substraat van dit enzym, dmFANCD2. Dit betekent waarschijnlijk dat de fruitvlieg
een eenvoudiger vorm van de FA biochemische route bezit. Om deze reden is dit
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organisme interessant als model om de functie FANC eiwitten beter te kunnen
begrijpen. De eerste resultaten over dit onderwerp worden besproken in
hoofdstuk 6.
     De resultaten in dit proefschrift tonen aan dat het toch mogelijk is om
weeseiwitten, zoals FANCG, FANCA, FANCC en FANCD2, te classificeren in een reeds
bekende familie van eiwitdomeinen. Dit betekent dat de meeste weeseiwitten
waarschijnlijk ontstaan zijn tijdens de evolutie door duplicatie van een reeds
bestaand gen. Een alternatief mechanisme waarbij willekeurig voorkomende open
reading frames (ORFs) in het genoom gebruikt worden om nieuwe genen te laten
ontstaan zal om deze reden minder belangrijk zijn voor FANC eiwitten. De
ontwikkeling en toepassing van gevoeliger database zoekalgoritmen zal
waarschijnlijk leiden tot een afname van het aantal weeseiwitsequenties in de
database. Op dit moment zijn ongeveer 10 tot 30 procent van alle voorspelde open
reading frames geclassificeerd als weeseiwitten.
     Opmerkelijk is dat behalve voor FANCL geen enkel eiwit uit het FA kerncomplex
een enzymatisch domein bezit. Dit betekent waarschijnlijk dat de totale ruimtelijke
structuur van het complex samen met mogelijke conformatieveranderingen het
belangrijkste kenmerk van het complex zal zijn. Mogelijk vertoont om deze reden
het FA kerncomplex veel overeenkomst met het ATM eiwit. ATM is een zeer groot
eiwit van 3056 aminozuren en is, op een klein PI3-kinase domein in de C-terminus
na, volledig samengesteld uit HEAT-repeats. Single-particle electron microscopy
experimenten die zijn uitgevoerd door Llorca et al. (2003) hebben aangetoond dat
ATM is samengesteld uit een ‘head’ en ‘arm’ domein. Na binding van ATM aan DNA
verandert de conformatie van het ‘arm’ domein en wikkelt deze zich om de DNA
keten heen. Het FA kerncomplex functioneert mogelijk op een vergelijkbare wijze.
De ruimtelijke structuur van het complex zou een bepaalde DNA structuur kunnen
herkennen, mogelijk ‘stalled replication forks’ of andere tussenvormen van het DNA
herstelproces. Binding van het FA kerncomplex aan deze DNA structuur induceert
vervolgens een conformatie verandering waarna de E3 ligase activiteit van FANCL
vrijkomt en het FANCD2 geactiveerd wordt door monoubiquitylering. In de nabije
toekomst zal de toepassing van röntgen diffractie, NMR en single-particle electron
microscopy technieken een bijdrage leveren aan het verder ophelderen van de
functie van de FA biochemische route en op welke wijze deze route bijdraagt aan
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